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LIST OF ABREVIATIONS 
 
18FDG-PET scan 
18F-deoxyglucose Positron Emission Tomography 
Scan 
ATP Adenosine Triphosphate 
AUA American Urology Association  
AUC Area under the Curve 
BPH  Benign Prostatic Hypertrophy 
CT Computer Tomography 
DAB 3,3′-Diaminobenzidine  
DRE Digital Rectal Examination 
EAU European Association of Urology 
EDIM Epitope Detection in Monocytes  
H&E Hematoxylin and Eosin  
IHC Immunohistochemistry 
LHRH luteinizing-hormone-releasing hormone  
MRI Magnetic Resonance Imaging 
NADPH Reduced form of Nicotinamide Adenine Dinucleotide 
PCA Prostate Cancer 
PSA Prostate-specific Antigen 
RCT Randomized Clinical Trials  
ROS Reactive Oxygen Species  
TKT Transketolase 
TKTL1 Transketolase-like 1 
TMA Tissue Microarray 
TNM Tumour Node Metastasis Classification 
TURP Transurethral Resection of the Prostate  
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1 INTRODUCTION 
 
Prostate cancer is the second most common cancer among men worldwide, so 
an urgent need exists for new diagnostic, prognostic and predictive tests.  The 
intent of developing new tests would be to reduce the number of unnecessary 
biopsies (pre-diagnostic tests), identify the aggressiveness of the disease, 
predict disease progression, predict biochemical recurrence and survival (post-
diagnostic tests), and hopefully offer better detection rates and disease 
monitoring. 
Prostate cancer is a heterogenic cancer, with numerous aggression levels and 
outcomes. In this study we intend to better understand the molecular 
pathogenesis of prostate cancer, specifically glucose metabolism deregulation. 
This thesis hypothesizes that glucose metabolism deregulated markers – 
TKTL1 – may play a role in the tumorigenesis of prostate cancer. 
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1.1 BACKGROUND: PROSTATE CANCER 
1.1.1 EPIDEMIOLOGY  
Prostate cancer is the second most common cancer among men worldwide 
(excluding non-melanoma skin cancer), with nearly 1,1 million new cases in 
2012 [1].  
In 2012 in Europe, prostate cancer was the most common cancer among men, 
and lung cancer the second most common. Prostate cancer has an estimated 
incidence for European men of 92.1 per 100,000 inhabitants, which places it 
first in incidence, but not in mortality ranking — lung and colorectal cancers 
occupy the top spots of that chart [2]. 
Germany's incidence rate of prostate cancer is higher than in the rest of Europe 
at 114.1 per 100.000 inhabitants, but the mortality rate in Germany is lower 
(17.8 per 100,000 inhabitants). In 2012, 63,710 new cases of prostate cancer 
were detected in Germany, being the prognosis for 2016 of 66,900 men. The 
most common T stage at diagnosis was T1 (27%) and T2 (48%), between ages 
70-74 and more than 85 [3].  
 
1.1.2 RISK FACTORS 
In comparison to other common cancers, the etiology is still not well 
understood, and the only three risk factors established are age, ethnicity and 
family history. 
Ageing increases the risk of prostate cancer. Autopsies confirm the prevalence 
of prostate cancer increases with age [4], and is mainly detected in patients  
older than 50. Almost half the population older than 70 years of age had 
prostate cancer [5]. 
Prostate cancer incidence varies among countries and continents; ethnic 
origin is considered a well-established risk factor. Asians have the lowest 
incidence while Australians and New Zealanders have  higher rates [1]. 
Disparities between races might be caused by environmental and/or genetic 
conditions. Observational studies of prostate cancer in migrant inhabitants show 
Japanese migrants (a country with low incidence) in the United States (high 
incidence) will show a rise in prostate cancer rates after immigrating [6].  
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The last well-established risk factor is hereditary. A study by Morganti et al. in 
1956 described familial aggregation in prostate cancer, in men who had 
relatives with the disease [7]. The probabilities of having prostate cancer is 
higher for men with a stronger family history [8]. 
 
 
 
 
Diet, lifestyles and potential exposures may influence the development and 
incidence of prostate cancer worldwide. Currently there is no strong evidence to 
suggest or recommend alterations in diet or lifestyles to reduce the risk of 
prostate cancer [9]. 
 
1.1.3 CLASSIFICATION 
1.1.3.1 GRADING SYSTEM  
When prostate cancer is diagnosed it is graded histologically. The current 
grading system was created by D.F. Gleason in 1966 [10], and since then has 
been slightly modified [11,12]. It still remains one of the most powerful 
prognostic tools in prostate cancer [13]. 
The Gleason system is an architectural assessment of hematoxylin and eosin 
stained prostatic tissue sections based on a low-power microscopic (10x–40x) 
assessment. The architectural changes are classified from 1 to 5 — the higher 
the number, the less normal the cells are (poorly differentiated).  
To assign a Gleason score/sum, the pathologist sums the Gleason grade of the 
2 most common types of glandular growth patterns within the tumour, this 
means the Gleason score ranges from 2 to 10. A sum of 7 can result from 3+4 
or 4+3, and Gleason score 3+4=7 does not have the same prognostic outcome 
as a Gleason score 4+3=7, the latter having a worse prognostic outcome, but 
both are placed in the same prognostic group (in D’Amico risk classification) 
[14,15]. Grades 1 and 2 closely resemble normal tissue and are rarely 
diagnosed [16], so the diagnosis is almost always undergraded. Grades 1 and 2 
are often an incidental finding in transition zone carcinomas in specimens 
Definition of hereditary prostate cancer 
Three or more affected relatives 
or 
At least two relatives who developed early-onset disease (before age 55) 
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extracted from transurethral resection of the prostate (TURP). In 2000, Epstein 
mentioned that Grade 1 and 2 on needle biopsies should not be made, leading 
to a narrowing of possible Gleason sum results, from 6 to 10 [17].  
Recently a new alternative grading system for prostate cancer has been 
validated that overcomes these previous deficiencies (see Table 1) [18].  
 
 
 
 
 
 
 
 
 Table	1:	Modified	Gleason	score	-	2014	International	Society	of	Urological	Pathology	(ISUP)	
 
 
1.1.3.2 STAGING SYSTEM 
 
The staging system used in prostate cancer is the Tumour Node Metastasis 
(TNM) Classification, an anatomically based system describing the primary and 
regional nodal extent of the tumour and the presence or absence of 
metastases. TNM is a dual staging system that includes a clinical (pretreatment) 
and a pathological (postsurgical histopathological) classification (see Table 2). 
 
Primary tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour not palpable or visible by imaging 
T1a Tumour incidental histological finding in 5% or less of tissue resected 
T1b Tumour incidental histological finding in more than 5% of tissue resected 
T1c Tumour identified by needle biopsy (e.g. because of elevated PSA level)  
T2 Tumour confined within the prostate 
T2a Tumour involves one half of one lobe or less 
T2b Tumour involves more than half of one lobe, but not both lobes 
T2c Tumour involves both lobes 
T3 Tumour extends through the prostatic capsule 
T3a Extracapsular extension (unilateral or bilateral) including microscopic 
bladder neck involvement 
T3b Tumour invades seminal vesicle(s) 
ISUP Modified Gleason Grading 
Group 1 Gleason score ≤6 
Group 2 Gleason score 3 + 4 = 7a 
Group 3 Gleason score 4 + 3 = 7b 
Group 4 Gleason score 8 
Group 5 Gleason score 9-10 
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T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: 
external sphincter, rectum, levator muscles, and/or pelvic wall 
Regional lymph node  
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
 Table	2:	TNM	Classification	–	Prostate	cancer	
 
 
1.1.3.3 EAU RISK GROUP CLASSIFICATION 
 
The EAU risk group Classification is essentially based on D’Amico’s 
classification system. The D’Amico classification was created in 1998 to stratify 
patients with prostate cancer into 3 groups: low, intermediate and high-risk of 
biochemical recurrence after surgery (see Table 3). The parameters used 
included the clinical TNM classification, biopsy Gleason score and preoperative 
PSA-levels [19]. 
 
 Table	3:	EAU	risk	group	classification.		GS:	Gleason	Score,	PSA:	Prostate	specific	antigen	
 
 
Since Gleason scores 7a and 7b don’t have the same outcome [20], a 
modification of the EAU risk group classification due to the implementation of 
the new Gleason grading might be needed in the near future.  
 
 
 
Low risk Intermediate High risk 
PSA < 10 ng/mL 
And GS < 7 
And cT1-2a 
PSA 10-20 ng/mL 
or GS 7 
or cT2b 
PSA >20 ng/mL 
or GS >7 
or cT2c 
Any PSA 
any GS  
cT3-T4 
or cN+ 
Localized Locally advanced 
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1.1.4 DIAGNOSIS 
1.1.4.1 PSA BASED SCREENING 
 
PSA is a glycoprotein secreted by the prostatic cells into the glands’ lumen. Its 
function is believed to be liquefy the seminal fluid (proteolysis of semenogelin I, 
SEMG1 and SEMG2) when activated in the lumen [21]. PSA is produced in 
normal, in benign prostatic hypertrophy (BPH) and in prostate cancer. When 
there is a disruption of the basal membrane and a distortion of the normal 
architectural configuration of the gland happens, PSA leaks (exaggeratedly) into 
the circulatory system leading to a rise in the serum PSA. This PSA-leakage 
and rise in serum can occur in normal tissue, during infection, in BPH or in 
cancer [22]. So using total PSA as a single element to detect prostate cancer is 
risky and not recommended.  
 
Using the PSA-testing alone for screening is not recommended, but a new 
concept was introduced: early diagnosis [9]. Early diagnosis/opportunistic 
screening is still recommended on an individual basis under certain 
circumstances. The AUA Guidelines do not distinguish screening and early 
diagnosis, indicating both early detection and screening imply detection of 
disease at an early, pre-symptomatic stage when a man would otherwise have 
no reason to seek medical care — an intervention referred to as secondary 
prevention [23]. In contrast, EAU Guidelines / recommendation differentiate 
mass screening from early detection distinctly, the latter requiring an informed 
consent from the patient following a discussion about the pros and cons of PSA 
based screening [9]. 
 
A threshold of total PSA >4ng/ml was proposed to detect prostate cancer, but 
this has remained controversial from the beginning [24]. PSA works as a 
biomarker with diagnostic, predictive and prognostic [25] properties, but its use 
has limitations, so the need to find new biomarkers remains [26]. PSA can be 
present in blood in a variety of forms, the majority bound to protease inhibitors 
— complexed PSA. The non-complexed form of PSA is called free PSA. The 
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free PSA ratio test can be used to help differentiate BPH from prostate cancer, 
especially when total PSA values vary between 4 and 10 ng/ml, values which 
are often difficult for the urologist to interpret and act upon (See Table 4.) [27].  
 
 
 
 
 	Table	4:	Probability	of	cancer	based	of	free	PSA	when	total	PSA	lies	between	4	and	10ng/ml	[28]		
1.1.4.2 DIGITAL RECTAL EXAMINATION (DRE) 
The zone palpated during DRE is the peripheral zone, where most prostate 
cancers are located. A clinical suspicion of DRE and/or PSA levels usually lead 
to a prostate biopsy, although this decision is normally not so straightforward as 
wished. An abnormal DRE is always an indication for a prostate biopsy [9]. 
 
1.1.4.3 BIOPSY 
Diagnosis of prostate cancer must be confirmed with a needle prostate biopsy. 
A transrectal approach is used more frequently, although a perineal approach is 
also possible. The number of core biopsies recommended is between 10 to 12 
under transrectal ultrasound guidance [28]. Other approaches exist, but they will 
not be mentioned in this thesis.  
 
1.1.5 TREATMENT OPTIONS 
Treatment options for prostate cancer are vast and may sometimes elicit 
contradictory opinions. It is beyond the scope of this thesis to describe all 
available treatment options in detail. 
 
1.1.5.1 WATCHFUL WAITING 
Tumour growth is relatively slow and constant in many patients, so this 
treatment option should be given to those with localized disease ineligible for 
local curative treatment, or with a life expectancy less than 10 years [29]. If the 
Total PSA, ng/ml Free PSA, %       Probability of cancer, % 
4-10 0-10 56 
 10-15 28 
 15-20 20 
 20-25 16 
 >25 8 
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patients develop disease-related symptoms in the future, palliative therapy 
should be offered to improve quality of life. These measures might include 
transurethral resection of the prostate (TURP), hormonal therapy, or 
radiotherapy. 
 
1.1.5.2 ACTIVE SURVEILLANCE 
To avoid overtreatment of men with low-risk prostate cancer, active surveillance 
should be offered. In contrary to watchful waiting, active surveillance has a 
curative intent. The patient should be under a regular follow-up schedule, 
including PSA-testing and DRE, with eventual biopsies and MRI to determine 
the optimal time for curative treatment. It appears active surveillance reduces 
the overtreatment rate, is safe [30], and does not compromise the overall 
survival compared to  patients receiving upfront local curative therapy [31].  
 
1.1.5.3 RADICAL PROSTATECTOMY 
This surgery includes removal of the prostate, part of the urethra, seminal 
vesicles, and surrounding tissue to obtain a negative margin. Bilateral pelvic 
lymphadenectomy should be performed in patients with an intermediate or high-
risk. The surgery can be performed as an open surgery, minimal invasive as 
either laparoscopic or robotic assisted [32]. The robotic assisted radical 
prostatectomy is becoming more common, probably due to the lower rate of 
complications [33], including decreased blood loss, blood transfusions, and 
hospital stay duration. [34] Most importantly, the oncological and functional 
outcome is similar to open surgery [35,36].  
 
1.1.5.4 RADIOTHERAPY 
Radiotherapy is also commonly used as a curative treatment. It may be offered 
to patients with low risk prostate cancer without locally advanced disease. It can 
be given alone, in combination (with hormone therapy), as an salvage agent 
when PSA increases, or in a multimodalidity setting in patients with locally 
advanced cancer or in N1 Stage (pelvic external irradiation). 
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While there are multiple approaches in radiotherapy, two of the most used in 
prostate cancer are: External-beam radiotherapy, consisting of high-energy 
radiation beams administered on a daily basis as an outpatient therapy. The 
recommended modality is the Intensity-modulated radiotherapy (IMRT) [37], 
Here, the clinician can alter the intensity according to the target volume and 
proximity to pelvic organs [38]. Brachytherapy is another option, preferentially 
given to patients with low risk assessments. Here radioactive seeds (around 
100 in number) are inserted in the prostate gland working locally [39]. 
Brachytherapy has been shown to be an effective treatment for low-risk and 
low-intermediate-risk prostate cancer [40].  
 
1.1.5.5 HORMONE THERAPY 
Prostate growth is regulated by androgens (testosterone and 
dihydrotestosterone [DHT]). Initially, PC usually is dependent on androgens for 
growth and survival, so androgen suppression in patients with advanced 
prostate cancer is recommended, a process known as castration [41]. One of 
the earliest forms of castration performed was the bilateral orchiectomy and the 
use of oestrogens, including Diethylstilbestrol, but in 1960s the VACURD study 
revealed the use of oral oestrogen to lower serum testosterone was associated 
with high cardiovascular morbidity and mortality [42–44]. 
In the 1960s and 1980s new therapy forms started to develop, involving 
inhibition of testicular androgen secretions or inhibition of the circulating 
androgens’ action, or a combination of these two pathways.  
Currently the main type of hormone therapy is the long-acting luteinizing-
hormone-releasing hormone agonists, also known as analogues of LHRH. 
Another form of hormone therapy is the LHRH antagonist which, in contrast to 
the previous therapy, will directly block LHRH receptors, achieving an earlier 
state of castration and avoiding the flare-up phenomenon. The third group 
includes the anti-androgens, which block the effects of adrenal androgens at the 
androgen receptor. 
 
 
11 
Castration is achieved when both PSA and testosterone remain below certain 
thresholds. If during treatment there is a progression in PSA-levels even though 
an optimal castrate serum testosterone is present, we are faced with a 
castration-resistant prostate cancer. Here other therapy options should come 
into play, including abiraterone acetate (CYP17 inhibitor), enzalutamide (novel 
anti-androgen) or chemotherapy. Examples of chemotherapeutic agents used 
include docetaxel and cabazitaxel [45]. 
 
 
 
 
1.1.6 OVERVIEW OF DISEASE PROGRESSION 
 
 
 
 
Biochemical	Recurrence Castrate	Resistant	Prostate	
Cancer
Local	Therapy Androgen	Deprivation	Therapy Chemotherapy
Time
Figure	 1:	 Overview	 of	 the	 alterations	 in	 testosterone	 and	 PSA	 along	 prostate	 cancer	 progression.	 An	increase	 in	 tumour	 activity	 after	 local	 therapy	 is	 indicated	 by	 rising	 in	 PSA	 levels,	 described	 as	biochemical	 failure	 or	 recurrence.	 The	 next	 step	 will	 be	 initiating	 a	 medical	 castration,	 which	 will	reduce	 the	 testosterone	 levels,	 diminishing	 the	 tumour	 activity	 resulting	 in	 PSA	 levels	 decrease.	 The	period	of	 time	which	 the	 PSA	 levels	maintain	 low	during	hormonal	 therapy	 is	described	as	hormone	sensitive	prostate	cancer.		If	there	is	an	augmentation	of	the	tumour	activity,	it	will	be	showed	a	rise	in	PSA	even	though	testosterone	 level	maintains	low,	entering	 in	a	phase	of	hormone-resistance	prostate	cancer.	
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1.2 BACKGROUND: CANCER AND METABOLISM 
 
In recent decades, carcinogenesis has been intensively studied and great 
interest has been generated worldwide to discover the cure for cancer. In 2000, 
an article was published suggesting the existence of 6 traits normal cells must 
acquire to transform into malignant cells. These traits deregulate certain 
physiological pathways, leading to cellular instability. The 6 Hallmarks of cancer 
proposed are:  self-sufficiency in growth signals, insensitivity to growth-inhibitory 
signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis [46]. In 
the past 16 years, multiple experimental drugs were developed to target these 6 
characteristics. Although there has been intense research in a variety of areas 
including molecular biology, genetics, metabolism, and pharmacology, an 
optimal approach to cancer has not been yet found. However, new traits have 
been discovered, and four traits were proposed in 2011: Emerging Hallmarks 
include avoiding immune destruction and deregulating cellular energetics, 
and two enabling characteristics including tumour-promoting inflammation and 
genome instability and mutation [47].  
In this thesis the focus is especially on the emerging Hallmark -- deregulating 
cellular energetics.  
 
1.2.1 OVERVIEW OF GLUCOSE METABOLISM 
The organism is generally exposed to a constant supply of nutrients, 
maintaining equilibrium between nutrient availability and cell proliferation. 
Nutrient uptake and metabolism are highly regulated to prevent abnormal 
proliferation. An altered or reprogrammed metabolism is considered one of the 
hallmarks of cancer cells [48], in order to support their rapid proliferation and 
expansion across the body.  
Glucose is a key metabolite in human metabolism; the main purpose of glucose 
degradation is the generation of energy (Figure 2) — adenosine triphosphate 
(ATP). There are various pathways to metabolize storage or regenerate 
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glucose. The first step in glucose degradation is named glycolysis, which the 
end product is pyruvate and ATP. More ATP can be produced when the 
glycolysis process continues: in an aerobic condition, pyruvate will be 
transported to the mitochondrial matrix and converted in Acetyl-Coenzyme A 
(Acetyl-CoA) in two ways, or suffer a complete degradation/oxidation in the citric 
acid cycle, or for synthesis of cholesterol and fatty acids. When in anaerobic 
conditions, pyruvate will be converted in lactate, a process commonly found in 
red cells by absence of mitochondria [49]. It will be released in the bloodstream 
and recycled in the presence of oxygen. Another possible pathway for pyruvate 
is the synthesis of amino acids. When there is excess glucose, the cell will store 
it in the form of glycogen, to be broken down when needed.  
Another pathway, important for pentoses production is the pentose phosphate 
pathway (PPP). This pathway produces ribose from glucose concomitantly 
producing 2 reduced nicotinamide adenine dinucleotide (NADPH). The 
pentoses are needed for formation of DNA and RNA, and also work as 
cofactors in enzymes. The production of NADPH is important for other 
pathways, which need NADPH and to avoid or prevent oxidative damage by 
radicals [50]. PPP neither requires ATP nor produces it. If excess NADPH is 
generated, it will inhibit the pathway in a feedback process. Pentose in excess 
can transform back to glucose, a process involving numerous enzymes, 
including transketolase and transaldolase. Special attention will be given to the 
PPP and transketolase throughout the thesis.  
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1.2.1.1 RESEARCH IN GLUCOSE METABOLISM IN MALIGNANT CELLS 
 
Cancer cells exhibit enhanced glycolysis and in aerobic conditions tend to have 
increased glucose uptake and lactate secretion [51]. This metabolic 
phenomenon is known as “aerobic glycolysis” (see Figure 3). This finding was 
first described by Otto Warburg in the 1920s [52] and for historical reasons 
glucose degradation to lactate even in the presence of oxygen is also named 
Warburg effect. In spite of the low energy outcome of aerobic glycolysis, it 
seems to be advantageous for tumour cells to supress mitochondrial 
metabolism. This may lead to increased cell proliferation (deviation from 
apoptosis) and a faster growth of cells [53–56].  
In 1929, Herbert Crabtree replicated the findings of Warburg and also showed 
that high concentrations of glucose decreased mitochondrial function, a 
reversible phenomenon influenced by external/trigger factors, such as 
environment or genes [57,58].   
Pyruvate
Acetyl-CoA
Lactate
Amino acids
TCA
Nucleotide
Glucose Glycolysis
Fatty acids
Glycogen
Electron
Transport
Chain
PPP
Mitochondrion
Figure	2:	Overview	of	glucose	metabolism	in	normal	cells,	adapted	from	Pérez-Mancera	P.	et	al	2014	[188]			
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In the late 1970s, a growing interest in cancer regulation mechanisms and 
signalling pathways started to arise, and oncogenes emerged as an established 
field in the early 1980s [59,60]. First, oncogenes were discovered through the 
study of retroviruses [61]. In the past decades the impact of genetic mutations, 
tumour suppressors, and oncogenes has been massively investigated. But only 
in the last 20 years, a link between the regulators of cell division and cell 
metabolism has been discovered. Here, it was shown that alterations in cellular 
signalling pathways could lead to aberrant metabolic programming [62–65].  
It is becoming clear that many oncogenic signalling pathways (see Table 5), 
affect tumour cell metabolism in order to support their growth and survival.  
 
Regulatory factors Reviews 
PI3K pathway (PTEN, AKT1) [66–69] 
HIF1 and MYC [70]  
AMP-activated protein kinase. [71,72] 
P53 and OCT1 [73] Table	5:	Example	of	regulatory	factors	controlling	glycolysis	in	cancer	cells	
 
Glucose Glycolysis Pyruvate Lactate-02
Normal	cell
+02
Malignant	cell
+02
Normal	cells
Acetyl-CoA
TCA
Electron
Transport
Chain
Lactate
Warburg	effect
Figure	3:	Schematic	overview	of	glycolysis-	anaerobic	glycolysis	and	aerobic	glycolysis	in	the	presence	or	absence	of	oxygen,	adapted	from	Zhang	W.	Et	Al	2015	[189].	+O2	-	in	presence	of	oxygen;	-O2	-	in	absence	of	oxygen.	
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Increased knowledge of malignant cell metabolism is driving the discovery of 
new drug targets and new diagnostic tools. One example is the use of 18F-
deoxyglucose positron emission tomography scanning (18FDG-PET scan) for 
imaging of solid tumours. This diagnostic tool has clearly shown us Warburg’s 
findings in a macro scale — an accelerated glucose metabolism is the basis of 
18FDG-PET in detecting cancer [74].  
 
1.2.1.2 THE PENTOSE PHOSPHATE PATHWAY 
 
The pentose phosphate pathway is a major pathway for glucose catabolism and 
the main source of NADPH in the body. A series of reactions, called glycolysis, 
break down glucose. Some of the glucose-6-phosphate (first metabolite of the 
glycolysis process) is shunted from the glycolysis process and enters the 
pentose phosphate pathway. Here the glucose-6-phosphate will be broken 
down, but the end product will not be ATP as expected, but ribose-5-phosphate 
and NADPH (primary product of PPP) (see Figure 4). 
Ribose-5-phosphate - is a precursor to nucleotide, DNA and RNA synthesis.  
In cancer cells these are extremely important due to the high rate of 
proliferation. So a high flux of glucose in the PPP will help the tumour cell to 
divide rapidly [75].   
NADPH - is a reducing agent, needed to control reactive oxygen species (ROS) 
levels. Higher levels of ROS stimulate apoptosis. 
In cancer cells, due to increased metabolism, ROS levels will increase. NADPH 
helps maintain a better environment to promote cell growth by suppressing 
apoptosis [76].   
As shown in Figure 4, the PPP has 2 arms: an oxidative arm (non-reversible) 
and a non-oxidative arm (reversible). An important rate-limiting enzyme of the 
oxidative arm is the glucose-6-phosphate dehydrogenase. Its role in oncogenic 
metabolism and overexpression in multiple tumours has been described in 
different cancers [77,78], including cervical cancer [79], gastric cancer [80], 
hepatocellular carcinoma [81], colon cancer [82], clear-cell renal cell carcinoma 
[83], prostate cancer [84] and urothelial cancer [85].  
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 Figure	 4:	 Schematic	 overview	 of	 glycolysis,	 pentose	 phosphate	 pathway	 and	 respiration.	 PPP:	pentose	phosphate	pathway,	TCA:	tricarboxylic	acid,	adapted	from	Fets	L.	et	al	2013	[86]	
 
Other important enzymes from the non-oxidative arm are Transketolase (TKT) 
and transaldolase (TALDO), which have also been associated with oncogenic 
mechanisms, usually found overexpressed.  
 
1.2.2 TKTL1 
Transketolase is an important reversible rate-limiting enzyme that catalyzes 
several key reactions of the non-oxidative arm of the PPP. This enzyme, 
together with transaldolase, regulates and sustains the metabolic needs of the 
cells. Since the non-oxidative arm is reversible, TKT can either switch the flux to 
produce NADPH or to produce pentoses, depending on metabolic needs. In 
other words, TKT has a pivotal role as a reversible link between PPP and 
glycolysis (see Table 6). 
 
 
 
 
 
Mitochondrion
TCA
Electron
Transport
Chain
Glu G-6-P
F-6-P
F-1,6-B
G-3-P
1,3-BG
3-PG
2-PG
PEP
Pyruvate
Lactate
DHAP
6-Phosphogluconate Ribulose-5-P
X-5-P R-5-P
G-3-P S-7-P
E-4-P F-6-P
Nucleotide
Synthesis
TKTL1
TALDO
TKTL1
Oxidative	 arm	of	PPP
Gl
yc
ol
ys
is
Non-oxidative	 arm	of	PPP
Respiration
ATP
ATP
ATP ATP
NADPH NADPH
nucleus
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Table	6:	Characteristics	of	TKTL1	[86,87]	
 
Three human genes have so far been discovered: TKT-gene and TKT-like gene 
1 and 2 [87]. The TKTL1 protein is commonly expressed in the testis, thymus 
and retina. Of the three TKT gene family the TKTL1 plays an important role in 
carcinogenesis and is overexpressed in multiple tumours [88,89], including 
colonic and urothelial tumours [90,91], uterine cervix cancer [92], breast cancer 
[93], ocular adnexal tumours [94], non-small cell lung cancer [95,96], and 
esophageal squamous cell carcinoma [97].  
The presence of an overexpression of TKTL1 has also been linked to disease 
progression with variations in TKTL1 expression being described in different 
stages of disease. In some cases a correlation with patients outcomes has been 
found, although this association is not yet understood [57,98–101]. Discussion 
of this topic is still ongoing without consensus in the scientific community.  In a 
study from Kämmerer U et al. it was shown that the presence of TKTL1 was 
unrelated to either the rate of glucose consumption or lactic acid production 
[102]. A consensus regarding TKTL1 and its interactions and function has not 
been reached yet.  
 
1.2.2.1 TKTL1 IN CARCINOGENESIS 
 
As referred to earlier, TKTL1 expression is overexpressed in multiple tumours, 
presumably to enable cell survival by maintaining a rapid utilization of large 
amounts of glucose in the absence of oxidative stress. Cancer cells with a 
deregulated glucose metabolism tend to have a higher uptake of glucose, 
because ATP generation via glycolysis is less efficient than by oxidative 
phosphorylation.  In order to have a constant high rate of proliferation, cancer 
Gene TKTL1 in Xq28 
Structure Homodimer 
Molecular mass 74,2 kDa per monomer 
Active sites 2 identical, formed at the dimer interface between the PP domain and the 
Pyr domain 
Cofactor Divalent metal ions (Ca2+) 
Domains N-terminal PP 
Middle-terminal PYR 
C-terminal 
Coenzyme Thiamine diphosphate (ThDP) - biologically active derivative of vitamin B1 
Function Cell metabolism (glycolysis and PPP) 
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cells need to maintain a high level of metabolic activity, and counteract against 
apoptosis and reactive oxygen species. 
Although the glycolytic pathway produces lesser ATP (2 vs 36 ATP/mol 
glucose, in comparison with oxidative phosphorylation) it provides its own 
advantages, including: production of pentoses needed for synthesis of DNA and 
RNA as also NADPH redox equivalents, to reduce the reactive oxygen species 
[89,103]. Studies inhibiting and enhancing TKTL were conducted: 
• Inhibiting TKTL activity led to a suppression of tumour growth [104–107]  
• Activation of TKTL led to enhanced tumour growth [108]  
Most of the prior studies concluded that TKTL1 inhibition may emerge as a 
future oncological therapeutic target. 
 
 
1.2.2.2 EDIM-TKTL1 BLOOD TESTS 
 
A new EDIM blood test was developed as a result of prior studies, which 
showed a correlation between overexpression of TKTL1 and malignancy. This 
blood test uses the epitope detection in monocytes (EDIM) technology, the 
concept being that circulating macrophages in peripheral blood, which had 
contact with cancer cells, will carry present tumour-related material, in these 
case TKTL1. 
In 2012, a study revealed that EDIM-TKLT1 blood test had good agreement 
with 18FDG-PET/CT [109]. A 2013 presentation to the American Society of 
Clinical Oncology of EDIM-TKLT1 blood tests in breast cancer patients, showed 
a good concordance between the EDIM-test and clinical observations. In the 
same year, a study involving patients with colon carcinoma concluded that 
EDIM TKTL1 test might indicate metastasis earlier than established tumour 
markers [110]. However, the EDIM-TKTL1 blood test has not yet been approved 
for clinical application. 
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2 SCOPE OF STUDY 
 
The overall aim of this study was to investigate TKTL1 expression in tissue 
microarrays of human prostate cancer and benign prostatic tissue. More 
specifically, the aims of the study were as follow: 
 
• To identify expression differences in TKTL1 expression between prostate 
cancer and normal prostatic tissue, in order to detect if TKTL1 protein is 
integrated or plays a role in the vast network of pathways in 
tumorogenesis in prostate cancer.  
• To evaluate the expression of TKTL1 in different stages of disease, 
eventually helping to better understand the tumorogenic process of 
prostate cancer, questioning if glucose reprogramming is a cornerstone 
to its development and progression.  
• To evaluate the expression of TKTL1 with the clinical profile and 
pathological data of patients, to help detect if TKTL1 expression could 
bring more information about the outcome, progression and 
aggressiveness of the disease, and eventually helping to better manage 
patients with prostate cancer. 
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3 MATERIALS AND METHODS 
 
3.1 PATIENTS  
 
The study population consisted of 124 patients who had undergone surgery in 
the Department of Urology of the University Hospital of Tuebingen, between 
2003 and 2014. The median age of patients was 66 (62-70), ages were 
calculated as of time of operation. Specimens included were from 53 patients 
with previous histologically verified prostate cancer (through a transrectal 
ultrasound-guided prostate biopsy) who underwent radical prostatectomies, and 
45 specimens from patients with metastatic prostate cancer that underwent 
palliative TURP. Leading to a total of 98 patients with prostate cancer, in 
different stages of disease.  As negative controls, 26 patients without prostate 
cancer were also included. 
An informed consent was obtained from all patients and the ethic approval was 
obtained by the local ethics committee (842/2916B02). 
 
53 radical prostatectomy specimens were included in the study. This group of 
patients were men who had been diagnosed with prostate cancer. The patients 
did not receive preoperative chemotherapy, nor radiotherapy or any other type 
of treatment. From these specimens the goal was to retrieve 3 types of tissues, 
peritumoral tissue far and near the tumour and the tumoral tissue itself.  
 
The 26 benign specimens are from patients with benign prostatic hyperplasia 
who underwent TURP (n=11), transvesical prostatic adenomectomy (n=8), and 
also, from patients with muscle-invasive bladder cancer that underwent radical 
cystectomy (n=7). Usually a transvesical prostatic adenomectomy is chosen 
instead of TURP for multiple reasons, including high prostatic volume (over 100 
ccm) or other concomitant bladder pathologies, following bladder stones or 
diverticula. In the non-prostatic cancer group, patients with muscle-invasive 
bladder cancer were included who underwent a radical cystoprostatectomy, 
which consists of the removal the entire bladder, the prostate, part of the 
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urethra, seminal vesicles, and part of the vas deferens, which gave an 
opportunity to retrieve a normal prostatic specimen. In this group of patients, if 
prostate cancer or an infiltration of the known bladder cancer in the prostate 
was detected, the prostatic specimen was not included in the study. 
 
Patients who underwent palliative TURP had metastatic prostate cancer. 
Patients from this group developed obstructive voiding symptoms, which 
interfered with the quality of life, being a relatively common finding in the clinical 
practice. Although TURP is commonly performed in patients with BPH, TURP 
can also be a therapy for the relief of bladder outlet obstruction for patients with 
advanced or metastatic prostate cancer. 
This group of patients is relatively heterogeneous, in terms of different stages of 
disease concerning the TNM classification as also hormonal sensitivity of the 
disease, being either hormone sensitive prostate cancer or hormone refractory. 
Theses are two different stages of disease, the latter meaning a disease 
progression, marked by a consecutive elevation of PSA-levels under a 
castration level of testosterone, being conventionally used the level 20 ng/dl. 
 
The clinical information of the patients (26 benign prostatic tissues, 53 
prostatectomy specimens and 45 prostatic specimens from palliative TURP) 
was retrospectively reviewed and inserted in a database in Excel Software 
Program (2010, v14.0).  
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3.2 TISSUE SAMPLES 
 
Healthy normal tissue, prostate cancer and normal adjacent to prostate cancer 
tissue samples were obtained from formalin-fixed and paraffin-embedded 
blocks from the Department of Pathology in the University Hospital of Tübingen. 
All specimens were previously submitted for pathological evaluation in 
Department of Pathology. All prostatectomy specimens were submitted for 
routine histological investigation, including measurements (vertical, transverse 
and sagittal), weight, histological type, location of tumour, extraprostatic 
extension, seminal vesicle invasion, bladder neck invasion, perineural invasion, 
Gleason grade, TNM classification, lymphovascular invasion, as also resection 
margins. Normal prostatic specimens retrieved from TURP, transvesical 
prostatic adenomectomy and radical cystectomy were also routinely analyzed in 
the Department of Pathology.  
The specimens were conserved in 4% Formalin fixed and paraffin-embedded in 
room temperature; paraffin embedding offers a good option for long-term 
preservation of tissue samples.  
For the purpose of the study, a pathologist reviewed all hematoxylin and eosin 
stained slides to confirm the target diagnosis, and marked where the tissue 
would be punched to construct the tissue microarray block. 
 
 
 
3.3 TISSUE MICROARRAY (TMA) 
3.3.1 TISSUE MICROARRAY (TMA) TECHNOLOGY 
The tissue microarray technology is a technique to amount multiple biological 
samples on a single solid support. In 1998 in Nature Medicine, Kononen et al. 
described the use of this technique, mentioning that as many as 1000 cylindrical 
tissues biopsies from different tissues could be distributed in a single tissue 
microarray - in a single slide [111]. 
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Before the TMA is constructed, the histological blocks will be stained with 
hematoxylin and eosin (H&E) and reviewed by a pathologist to confirm, if the 
slide is representative of the block. If so, the pathologist will mark the areas of 
interest, where the needed cores will later on be removed. The cylindrical tissue 
cores’ typical sizes are 0.6 mm, 1.0 mm, 1.5 mm and 2.0 mm and the number of 
cores varies with size of tumour, size of population and purpose of the study. 
When building the TMA block (see Figure 5), controls should be placed on each 
of them, existing a variety of tissues options, to help the examiner to navigate.  
The pathologist should review the TMA sections (stained with H&E) to confirm if 
the previous marked areas are present in the TMA final section.  
This method reduces time, as well cost, reagent usage, storage place and 
reduce experimental heterogeneity - all cores are treated identically (the 
variables, including temperature and preparation method will be the same for all 
cores). A potential point of criticism of TMA, is that the cores are small in size, 
and may lead to a misrepresentation of specimens, especially when 
heterogeneous [112]. The scores given in the tissue microarrays are not always 
coherent to the scores given in the whole section [113,114]. Studies concluded 
that when multiple cores from the same area are included, the TMA’s 
representativeness increases [115]. 
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Figure	5:	Schematic	overview	of	the	process	of	tissue	mircroarray	construction	and	immunohistochemical	staining	
Figure	6:	Placement	of	the	cores	in	the	recipient	block.	Source:	Instructional	Manual	of	MTA-1,	Beecher	Instruments	Inc.	
Donor Blocks
Tissue cores
Recipient Block
Tissue Mircroarray
Tissue	Microarray	
Construction
Immunohistochemical staining of 
tissue array specimens
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3.3.2 DESCRIPTION OF THE PROCESS 
Formalin-fixed and paraffin-embedded preparations of radical prostatectomy 
specimens were evaluated and the pathologist marked the areas of tumour and 
areas of benign tissue, after which the samples could be arrayed. Benign 
tissues of the prostatectomies were divided in 2 groups: near and far from 
tumour. From each case were retrieved at least two to six replicates of each 
area, to ensure an adequate number for the statistical analysis, knowing that a 
loss of up to 10% of tissue samples is normal after tissue preparations. The 
same number of punches was retrieved from normal tissues with BPH as also 
malignant tissues obtain by palliative TURP cases. 
The block from which the histocores were taken is referred as donor block, and 
the histocores were placed into the recipient block. The tissue microarray 
instrument (MTA-1, Beecher instruments, Sun Prairie, WI, USA) (see Figure 6), 
used is designed to produce circular cores that are 1mm in diameter, and the 
core were placed at a specifically coordinate. TMA maps were recorded using 
Microsoft Excel.  
 
Using a microtome (Leica RM-2125 RT, Wetzlar, Germany) (see Figure 7), 5-10 
μm sections were cut from the microarray blocks’ generating the tissue 
microarray slides for the immunohistochemical analyses. In total of 12 
microarrays slides were obtained in this study, each containing around 8x4 to 
8x6 cores (see Figure 8). 
 
A pathologist to ensure that the histocores were taken from the wished areas, to 
detect eventually punches from wrong areas or to detect artefacts, evaluated 
the final TMA slides. 
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 Figure	7:	Microtome	(Leica	Rm-2125	Rt)	Source:	Leica	Biosystems	
 
 
 
 
 
 
 
 
 
 
  
 Figure	8:	Example	of	a	TMA	slide	(left)	containing	56	tissue	samples.	The	complete	TMA	comprises	12	sections	with	a	total	of	642	samples.	Schematic	layout	of	the	TMA	section	(right).	
 
 
3.4 IMMUNOHISTOCHEMICAL STAINING OF TISSUE ARRAY SPECIMENS 
3.4.1 IMMUNOHISTOCHEMISTRY 
Commonly, immunohistochemistry is used as a laboratory technic to interpret 
the TMA material, including in the field of research. 
IHC is used routinely in oncology to help distinguish benign from malignant 
cells, detect prognostic factors, subtyping neoplasia, detect primary site of 
malignant cells in undifferentiated neoplasia [116,117].  
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IHC is a method used to detect certain cell types or tissue antigens, inspired in 
different scientific disciplines, immunology, biochemistry and histology. The 
concept behind this method is that the binding of an antibody and an antigen in 
specific tissue sections will be enhanced through a histochemical process or 
with fluorochromes, being visible under an ultraviolet light. The bind between 
antibody and antigen is not visible under the microscope, here it will be applied 
a substrate which will be converted by an enzyme to an insoluble colored 
product that is deposited at the area of antigen expression – chromogenic 
detection. Dealing with IHC has two steps: the process of staining and secondly 
the interpretation and quantification of the expression.  
 
 
IHC often aids in the diagnosis of prostate cancer. Its diagnosis is based in 
morphological characteristics, but in some cases the tumour is so 
undifferentiated or the morphology assembles a benign tissue, which leads to 
the need of other methods to better interpret the specimens. 
It is known that absence of basal cells is one of the major criteria to diagnose 
prostate cancer [118,119]. Important immunohistochemical stains, specifically 
basal cell markers (CK HMW, CK 5/6, CK 14) are used to help to detect 
malignancy or not. Another example of the applicability of IHC in prostate 
cancer is to distinguishe from other malignant cells, including urothelial cancer 
which usually express positivity for p63, while prostate cancer does not 
[120,121] or Prostein which in contrary is expressed in prostate cancer and not 
in urothelial carcinoma [122]. To distinguish between colorectal cancer, CK20 
and CDX2 are used, which CDX2 is not expressed in prostate cancer and is 
expressed in colorectal cancer [123,124].   
 
Some other important immunohistochemical stains include: AMACR, PSA, 
PSAP, CK AE1/AE3 [125,126].  
 
As purpose of the study, we used a monoclonal antibody (murine) commercially 
available, named JFC12T10, which recognizes and binds to the C-terminal 
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fragment of recombinant TKTL1 protein molecule present in the tissues 
samples. These antigen-antibody complexes are then only detected after 
treatment of the tissue samples, with various methods mentioned below. For the 
chromogenic process, 3,3′-Diaminobenzidine (DAB) was used, which results in 
the formation of an insoluble color precipitate, brown-red-pink, which can be 
good distinguished from the blue Mayer's Hematoxylin Counterstained cells 
under a light microscope. Immunohistochemical stain with JFC12T10 antibody 
shows a cytoplasmatic staining in certain prostatic cells. 
 
Positive controls should be performed in each test for quality control purposes, 
it helps to detect any disturbances in the functionality of the anti-TKTL1 
antibody. In this study TKTL1- stained testicular tissue specimens were used as 
positive controls, because it is known that TKTL1 expression is found in high 
levels in this type of tissue [127]. As negative control, the antibody was omitted 
on testicular tissue to show absence of staining. 
 
Although IHC has really good properties, being an advantage comparing to 
other methods, due to its easy availability, low cost, quick method it has also its 
own disadvantages. Reading/Interpretation method is a subjective interpretation 
and there is currently no standardization. The expression of certain protein is an 
indirect detection and it’s subject to various potentially preparation bias (dilution, 
dehydration, staining, fixation, antigen retrieval). The interpretation of the 
expression will be more detailed during the thesis. 
 
 
 
3.4.2 DESCRIPTION OF THE PROCESS 
The first section was stained with H&E for histological review. Additional 
sections served for immunohistochemistry.  
Formalin-fixed and paraffin-embedded sections (5-10 μm) of matched normal 
and cancerous tissue were dewaxed using Xylol (3 times 10 minutes), 
rehydrated in a series of graded alcohols and rinsed with distilled water, in a 
sequence of 2 times 5 minutes with 100% Ethanol, 2 times 5 minutes 96% 
Ethanol and 1time 5 minutes with 70% Ethanol. Pre-treatment with 3% 
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Hydrogen peroxide, H2O2, (for 20 minutes) for inactivation of endogenous 
peroxidase was performed, and then rinsed with distilled water for 5 minutes. 
The antigen retrieval step was performed using sodium citrate buffer (pH 6.0) 
and exposure to high energy in a microwave for 2 x 5 minutes. Slides were 
allowed to cool down for 30 minutes in room temperature and then washed with 
TBST (0.05M Tris pH 7.6; 0,15M NaCl; 0.1% Tween 20) 2 x 5minutes. 
Subsequently, slides were incubated for one hour in room temperature with 
monoclonal mouse anti-TKTL1 antibody (clone JFC12T10, Monocolonal Mouse 
IgG2b; Vector Linaris, Darmstadt, Germany) diluted (1:800) in antibody diluent 
(DAKO Real Antibody Diluent, Glostrup, Denmark). After 3 x 5 minutes washes 
in TBST, Advance Horseradish Peroxidase HRP Link (Advance kit, Dako, 
Glostrup, Denmark) was applied to the slides for 30 minutes in room 
temperature. Sections were washed in TBST 3 x 5 minutes, and then it was 
incubated with Advance HRP Enzym (Advance kit, Dako, Glostrup, Denmark) 
for 30 minutes in room temperature. After incubation slides were washed in 
TBST 3 x 5 minutes and then the complex was visualized by adding ImmPACT 
DAB (1000µl Buffer + 20µl 3,3′-Diaminobenzidine (DAB), Burlingame, CA, USA) 
for 4 minutes, being afterward washed in TBST 2 x 5 minutes.  The slides were 
counterstained with Mayer's Hematoxylin Solution followed by a step of blueing 
where slides were under warm running tap water for 7 minutes.  Slides were 
dehydrated successively in 96% Ethanol 2 x 3minutes, 100% Ethanol 2 x 5 
minutes ended with 3 x 5 min with Xylol. To preserve the histochemical stain it 
was used the Vectamount Mouting medium (Burlingame, CA, USA).  
Appropriate positive and negative controls were included in each slide, 
testicular tissue. 
The slides were viewed by light microscopy (Axio, Zeiss Lab. A1, Oberkochen, 
Germany). Cores that were absent, folded, or contained an insufficient number 
of tumour cells were not scored, and therefore excluded. 
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3.5 SCORING SYSTEM FOR IMMUNOHISTOCHEMICAL STAINING 
 
There is still no consensus on a protocol for scoring of immunohistochemical 
staining. Numerous of different IHC evaluation scales are used nowadays. 
Some pathologists describe the immunoreactivity as negative, weak or strong, 
other studies use a more complex scoring system, by multiplying the 
percentage of positive cells (P) by the intensity staining (I) – weak staining (1), 
moderate staining (2) and strong staining (3).  
 
Q = P x I 
Minimum= 0; Maximum = 300 
 
A scoring system for TKTL1 was proposed as guide in breast tissues sections 
(paraffin-embedded) by the R-Biopharm AG, when presenting its product, 
RIDA®PentoCheck® IHC, which consisted of: 
 
Score 0: 0–20% of tumour cells exhibit TKTL1 staining 
Score 1: 21–50% of tumour cells exhibit TKTL1 staining 
Score 2: 51–80% of tumour cells exhibit TKTL1 staining 
Score 3: > 80% of tumour cells exhibit TKTL1 staining 
 
But since the cytoplasmatic staining with TKTL1 is heterogeneous in prostate 
tissue, the semiquantitative score should be more complex, and the chosen one 
for this study was the Histo-score (H-score). The fraction (in percentage) of cells 
would be multiplied by the stain intensity, negative (0), weakly positive (1), 
positive (2), strongly positive (3), in two different highly power fields. The 
product of the percentage of positive cells and staining intensity ranged score 
between 0 and 300 [128]. 
The sections were first evaluated at low power magnification. In 100x 
magnification the majority of strongly positive cases were easily detectable. The 
fraction of stained tumour cells was verified using a higher magnification of 
200x. When difficulty to classify the stained cells between score 1 and 2 
increased, a higher power field was used of 400x.  
 
32 
Each area of interest gave rise to more than one core, so the final H-score of 
the selected area was the average of all H-score of the corresponding area (see 
Figure 9 and 10). 
To score the histocores, each slide was examined twice by the same examiner 
on a light microscope (see Figure 11). The final score given was the average 
between the two examinations. Some cores were documented, and photos 
were taken using a digital camera integrated in the microscope.  
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Pathology 
Identification 
Number
K/2003/09763
K/2003/09763
K/2003/09763
K/2003/09763
K/2003/09763
K/2003/09763
K/2003/09763
K/2003/09763
K/2003/19149
K/2003/19149
K/2003/19149
K/2003/19149
K/2003/19149
K/2003/19149
K/2003/19149
K/2003/19149
K/2003/19149
K/2003/19149
K/2004/08600
K/2004/08600
K/2004/08600
K/2004/08600
K/2004/08600
K/2004/08600
K/2004/08600
K/2004/08600
K/2004/17591
K/2004/17591
K/2004/17591
K/2004/17591
K/2004/17591
K/2004/17591
K/2004/17591
K/2004/17591
K/2004/17591
K/2004/17591
K/2003/21131
K/2003/21131
K/2003/21131
K/2003/21131
K/2003/21131
K/2003/21131
K/2003/21131
K/2003/21131
K/2004/03522
K/2004/03522
K/2004/03522
K/2004/03522
K/2004/03522
K/2004/03522
K/2004/03522
K/2004/03522
K/2003/11690
K/2003/11690
K/2003/11690
K/2003/11690
K/2003/11690
K/2003/11690
K/2003/11690
K/2003/11690
K/2008/09832
K/2008/09832
K/2008/09832
K/2008/09832
K/2008/09832
K/2008/09832
K/2008/09832
K/2008/09832
K/2003/19088
K/2003/19088
K/2003/19088
K/2003/19088
K/2003/19088
K/2003/19088
K/2003/19088
K/2003/19088
K/2003/19088
K/2003/19088
K/2003/10494
K/2003/10494
K/2003/10494
K/2003/10494
K/2003/10494
K/2003/10494
K/2003/10494
K/2003/10494
K/2008/11554
K/2008/11554
K/2008/11554
K/2008/11554
K/2008/11554
K/2008/11554
K/2008/11554
K/2008/11554
K/2004/02784
K/2004/02784
K/2004/02784
K/2004/02784
K/2004/02784
K/2004/02784
K/2004/02784
K/2004/02784
K/2004/02784
K/2004/02784
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/14109
K/2008/11022
K/2008/11022
K/2008/11022
K/2008/11022
K/2008/11022
K/2008/11022
K/2008/11022
K/2008/11022
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02634
K/2004/02614
K/2004/02614
K/2004/02614
K/2004/02614
K/2004/02614
K/2004/02614
K/2004/02614
K/2004/02614
K/2004/08599
K/2004/08599
K/2004/08599
K/2004/08599
K/2004/08599
K/2004/08599
K/2004/08599
K/2004/08599
K/2004/00599
K/2004/00599
K/2004/00599
K/2004/00599
K/2004/00599
K/2004/00599
K/2004/00599
K/2004/00599
K/2004/00599
K/2004/00599
K/2008/12113
K/2008/12113
K/2008/12113
K/2008/12113
K/2008/12113
K/2008/12113
K/2008/12113
K/2008/12113
K/2008/12113
K/2008/12113
K/2008/12113
K/2008/12113
K/2003/08715
K/2003/08715
K/2003/08715
K/2003/08715
K/2003/08715
K/2003/08715
K/2003/08715
K/2003/08715
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2003/16920
K/2008/14732
K/2008/14732
K/2008/14732
K/2008/14732
K/2008/14732
K/2008/14732
K/2008/14732
K/2008/14732
K/2004/18098
K/2004/18098
K/2004/18098
K/2004/18098
K/2004/18098
K/2004/18098
K/2004/18098
K/2004/18098
K/2004/18098
K/2004/18098
K/2004/18098
K/2004/17694
K/2004/17694
K/2004/17694
K/2004/17694
K/2004/17694
K/2004/17694
K/2004/17694
K/2004/17694
K/2003/18464
K/2003/18464
K/2003/18464
K/2003/18464
K/2003/18464
K/2003/18464
K/2003/18464
K/2003/18464
K/2008/11815
K/2008/11815
K/2008/11815
K/2008/11815
K/2008/11815
K/2008/11815
K/2008/11815
K/2008/11815
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2004/02674
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
K/2008/13697
1st	Approach
100
40
100
80
160
#VALUE!
200
200
130
100
#VALUE!
80
120
80
0
#VALUE!
300
210
200
#VALUE!
100
200
100
130
220
130
0
0
#VALUE!
100
100
10
#VALUE!
200
#VALUE!
150
140
100
#VALUE!
100
#VALUE!
120
#VALUE!
200
140
60
#VALUE!
100
100
100
170
75
90
70
#VALUE!
170
180
120
100
60
240
240
115
100
170
#VALUE!
290
280
100
100
100
#VALUE!
100
120
100
110
300
245
#VALUE!
#VALUE!
120
100
200
100
#VALUE!
#VALUE!
140
#VALUE!
180
260
285
#VALUE!
#VALUE!
290
#VALUE!
190
110
140
160
210
280
#VALUE!
110
200
115
150
#VALUE!
150
140
150
200
#VALUE!
240
180
#VALUE!
300
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
170
100
170
300
250
220
140
180
240
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
300
290
#VALUE!
30
190
90
30
0
10
195
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
110
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
290
#VALUE!
85
180
280
260
280
295
#VALUE!
100
#VALUE!
290
120
#VALUE!
#VALUE!
#VALUE!
300
260
180
120
280
200
200
180
300
160
210
#VALUE!
100
170
#VALUE!
0
220
200
270
110
275
200
300
230
250
200
120
240
#VALUE!
#VALUE!
100
300
100
#VALUE!
100
225
100
100
200
160
100
200
200
180
180
100
200
#VALUE!
250
80
#VALUE!
120
#VALUE!
190
#VALUE!
100
#VALUE!
70
0
200
#VALUE!
200
290
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
280
#VALUE!
#VALUE!
230
280
2nd	Approach
100
100
100
100
180
#VALUE!
200
200
100
100
#VALUE!
100
180
100
0
#VALUE!
300
220
180
#VALUE!
100
190
100
130
180
130
0
0
#VALUE!
120
110
20
#VALUE!
230
#VALUE!
170
140
100
#VALUE!
100
#VALUE!
130
#VALUE!
200
110
80
#VALUE!
120
100
100
155
70
90
105
#VALUE!
170
160
100
100
80
240
260
110
100
180
#VALUE!
280
300
100
100
100
#VALUE!
100
115
100
100
300
240
#VALUE!
#VALUE!
100
100
200
160
#VALUE!
#VALUE!
140
#VALUE!
190
250
280
#VALUE!
#VALUE!
300
#VALUE!
180
100
120
190
180
270
#VALUE!
100
200
120
150
#VALUE!
100
135
160
200
#VALUE!
135
160
#VALUE!
260
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
110
100
180
200
220
200
140
170
220
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
280
300
#VALUE!
30
115
100
40
0
15
200
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
100
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
300
0
60
180
280
240
280
290
#VALUE!
100
#VALUE!
280
100
#VALUE!
#VALUE!
#VALUE!
300
270
100
120
290
170
200
180
280
160
100
#VALUE!
100
160
#VALUE!
0
210
205
280
100
280
220
300
220
270
200
200
240
#VALUE!
#VALUE!
120
300
60
#VALUE!
100
255
100
100
180
180
80
190
200
200
190
100
200
#VALUE!
270
100
#VALUE!
140
#VALUE!
200
#VALUE!
0
#VALUE!
50
100
205
#VALUE!
200
300
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
300
#VALUE!
#VALUE!
240
280
Average
100
70
100
90
170
#VALUE!
200
200
115
100
#VALUE!
90
150
90
0
#VALUE!
300
215
190
#VALUE!
100
195
100
130
200
130
0
0
#VALUE!
110
105
15
#VALUE!
215
#VALUE!
160
140
100
#VALUE!
100
#VALUE!
125
#VALUE!
200
125
70
#VALUE!
110
100
100
162,5
72,5
90
87,5
#VALUE!
170
170
110
100
70
240
250
112,5
100
175
#VALUE!
285
290
100
100
100
#VALUE!
100
117,5
100
105
300
242,5
#VALUE!
#VALUE!
110
100
200
130
#VALUE!
#VALUE!
140
#VALUE!
185
255
282,5
#VALUE!
#VALUE!
295
#VALUE!
185
105
130
175
195
275
#VALUE!
105
200
117,5
150
#VALUE!
125
137,5
155
200
#VALUE!
187,5
170
#VALUE!
280
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
140
100
175
250
235
210
140
175
230
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
290
295
#VALUE!
30
152,5
95
35
0
12,5
197,5
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
105
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
295
#VALUE!
72,5
180
280
250
280
292,5
#VALUE!
100
#VALUE!
285
110
#VALUE!
#VALUE!
#VALUE!
300
265
140
120
285
185
200
180
290
160
155
#VALUE!
100
165
#VALUE!
0
215
202,5
275
105
277,5
210
300
225
260
200
160
240
#VALUE!
#VALUE!
110
300
80
#VALUE!
100
240
100
100
190
170
90
195
200
190
185
100
200
#VALUE!
260
90
#VALUE!
130
#VALUE!
195
#VALUE!
50
#VALUE!
60
50
202,5
#VALUE!
200
295
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
290
#VALUE!
#VALUE!
235
280
Pathology 
Identification 
Number
K/2003/11719
K/2003/11719
K/2003/11719
K/2003/11719
K/2003/11719
K/2003/11719
K/2003/11719
K/2003/11719
K/2003/16598
K/2003/16598
K/2003/16598
K/2003/16598
K/2003/16598
K/2003/16598
K/2003/16598
K/2003/16598
K/2003/16598
K/2003/16598
K/2008/10811
K/2008/10811
K/2008/10811
K/2008/10811
K/2008/10811
K/2008/10811
K/2008/10811
K/2008/10811
K/2008/23464
K/2008/23464
K/2008/23464
K/2008/23464
K/2008/23464
K/2008/23464
K/2008/23464
K/2008/23464
K/2008/14318
K/2008/14318
K/2008/14318
K/2008/14318
K/2008/14318
K/2008/14318
K/2008/14318
K/2008/14318
K/2008/12558
K/2008/12558
K/2008/12558
K/2008/12558
K/2008/12558
K/2008/12558
K/2008/12558
K/2008/12558
K/2008/12558
K/2008/12558
K/2005/14306
K/2005/14306
K/2005/14306
K/2005/14306
K/2005/14306
K/2005/14306
K/2005/14306
K/2005/14306
K/2004/13012
K/2004/13012
K/2004/13012
K/2004/13012
K/2004/13012
K/2004/13012
K/2004/13012
K/2004/13012
K/2004/13012
K/2004/13012
K/2004/13012
K/2004/13012
K/2003/16508
K/2003/16508
K/2003/16508
K/2003/16508
K/2003/16508
K/2003/16508
K/2003/16508
K/2003/16508
K/2008/13437
K/2008/13437
K/2008/13437
K/2008/13437
K/2008/13437
K/2008/13437
K/2008/13437
K/2008/13437
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2003/20731
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/10812
K/2008/20512
K/2008/20512
K/2008/20512
K/2008/20512
K/2008/20512
K/2008/20512
K/2008/20512
K/2008/20512
K/2008/19946
K/2008/19946
K/2008/19946
K/2008/19946
K/2008/19946
K/2008/19946
K/2008/19946
K/2008/19946
K/2004/13837
K/2004/13837
K/2004/13837
K/2004/13837
K/2004/13837
K/2004/13837
K/2004/13837
K/2004/13837
K/2004/13837
K/2004/13837
K/2008/13860
K/2008/13860
K/2008/13860
K/2008/13860
K/2008/13860
K/2008/13860
K/2008/13860
K/2008/13860
K/2008/08983
K/2008/08983
K/2008/08983
K/2008/08983
K/2008/08983
K/2008/08983
K/2008/08983
K/2008/08983
K/2003/08200
K/2003/08200
K/2003/08200
K/2003/08200
K/2003/08200
K/2003/08200
K/2003/08200
K/2003/08200
K/2004/00598
K/2004/00598
K/2004/00598
K/2004/00598
K/2004/00598
K/2004/00598
K/2004/00598
K/2004/00598
K/2004/00598
K/2004/00598
K/2008/12640
K/2008/12640
K/2008/12640
K/2008/12640
K/2008/12640
K/2008/12640
K/2008/12640
K/2008/12640
K/2003/18465
K/2003/18465
K/2003/18465
K/2003/18465
K/2003/18465
K/2003/18465
K/2003/18465
K/2003/18465
K/2008/09434
K/2008/09434
K/2008/09434
K/2008/09434
K/2008/09434
K/2008/09434
K/2008/09434
K/2008/09434
K/2005/12827
K/2005/12827
K/2005/12827
K/2005/12827
K/2003/17044
K/2003/17044
K/2003/17044
K/2003/17044
K/2003/17044
K/2003/17044
K/2003/17044
K/2003/17044
K/2003/11008
K/2003/11008
K/2003/11008
K/2003/11008
K/2003/11008
K/2003/11008
K/2003/11008
K/2003/11008
1st	Approach
200
150
300
300
150
130
#VALUE!
190
110
100
100
110
100
100
180
100
#VALUE!
200
#VALUE!
80
#VALUE!
120
20
50
205
300
200
180
280
100
200
200
280
300
#VALUE!
300
200
200
300
#VALUE!
#VALUE!
280
#VALUE!
#VALUE!
230
#VALUE!
#VALUE!
#VALUE!
215
220
#VALUE!
300
20
100
#VALUE!
20
80
20
0
290
100
110
100
100
#VALUE!
#VALUE!
280
280
#VALUE!
#VALUE!
155
240
#VALUE!
#VALUE!
0
#VALUE!
#VALUE!
200
20
#VALUE!
130
300
250
200
240
220
290
205
130
#VALUE!
110
100
#VALUE!
170
200
300
170
100
#VALUE!
300
#VALUE!
100
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
170
#VALUE!
#VALUE!
130
#VALUE!
#VALUE!
#VALUE!
100
100
#VALUE!
160
#VALUE!
220
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
300
200
200
40
100
200
200
200
#VALUE!
200
200
290
#VALUE!
300
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
#VALUE!
140
100
#VALUE!
#VALUE!
#VALUE!
280
110
#VALUE!
#VALUE!
#VALUE!
#VALUE!
150
#VALUE!
#VALUE!
240
#VALUE!
90
60
#VALUE!
40
#VALUE!
#VALUE!
95
120
105
#VALUE!
230
#VALUE!
#VALUE!
#VALUE!
#VALUE!
300
300
#VALUE!
100
100
150
200
180
300
200
100
180
#VALUE!
#VALUE!
250
200
300
150
0
0
230
300
#VALUE!
#VALUE!
100
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
100
60
#VALUE!
100
50
#VALUE!
170
280
2nd	Approach
200
140
300
300
140
120
#VALUE!
180
130
100
100
120
100
100
160
100
#VALUE!
190
#VALUE!
90
0
110
40
60
245
300
160
180
270
100
200
210
300
300
#VALUE!
300
200
200
300
#VALUE!
#VALUE!
290
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
230
240
#VALUE!
300
10
100
#VALUE!
0
90
110
0
300
90
100
100
130
#VALUE!
#VALUE!
280
265
#VALUE!
#VALUE!
160
235
#VALUE!
#VALUE!
20
#VALUE!
#VALUE!
200
50
#VALUE!
140
280
230
200
230
240
300
180
100
#VALUE!
100
100
#VALUE!
180
100
290
180
0
#VALUE!
300
#VALUE!
100
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
180
#VALUE!
#VALUE!
115
#VALUE!
#VALUE!
#VALUE!
100
100
#VALUE!
180
#VALUE!
240
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
300
200
200
80
100
180
200
200
#VALUE!
200
200
290
#VALUE!
300
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
#VALUE!
110
100
#VALUE!
#VALUE!
#VALUE!
180
125
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
#VALUE!
#VALUE!
230
#VALUE!
95
50
#VALUE!
120
#VALUE!
#VALUE!
100
110
100
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
#VALUE!
300
280
#VALUE!
100
100
140
200
180
300
220
100
200
#VALUE!
#VALUE!
240
200
300
260
0
0
220
300
#VALUE!
#VALUE!
100
0
0
0
#VALUE!
200
100
50
#VALUE!
100
70
#VALUE!
180
270
Average
200
145
300
300
145
125
#VALUE!
185
120
100
100
115
100
100
170
100
#VALUE!
195
#VALUE!
85
#VALUE!
115
30
55
225
300
180
180
275
100
200
205
290
300
#VALUE!
300
200
200
300
#VALUE!
#VALUE!
285
#VALUE!
#VALUE!
215
#VALUE!
#VALUE!
#VALUE!
222,5
230
#VALUE!
300
15
100
#VALUE!
10
85
65
0
295
95
105
100
115
#VALUE!
#VALUE!
280
272,5
#VALUE!
#VALUE!
157,5
237,5
#VALUE!
#VALUE!
10
#VALUE!
#VALUE!
200
35
#VALUE!
135
290
240
200
235
230
295
192,5
115
#VALUE!
105
100
#VALUE!
175
150
295
175
50
#VALUE!
300
#VALUE!
100
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
175
#VALUE!
#VALUE!
122,5
#VALUE!
#VALUE!
#VALUE!
100
100
#VALUE!
170
#VALUE!
230
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
300
200
200
60
100
190
200
200
#VALUE!
200
200
290
#VALUE!
300
#VALUE!
200
#VALUE!
#VALUE!
#VALUE!
#VALUE!
125
100
#VALUE!
#VALUE!
#VALUE!
230
117,5
#VALUE!
#VALUE!
#VALUE!
#VALUE!
175
#VALUE!
#VALUE!
235
#VALUE!
92,5
55
#VALUE!
80
#VALUE!
#VALUE!
97,5
115
102,5
#VALUE!
215
#VALUE!
#VALUE!
#VALUE!
#VALUE!
300
290
#VALUE!
100
100
145
200
180
300
210
100
190
#VALUE!
#VALUE!
245
200
300
205
0
0
225
300
#VALUE!
#VALUE!
100
#VALUE!
#VALUE!
#VALUE!
#VALUE!
200
100
55
#VALUE!
100
60
#VALUE!
175
275
Pathology 
Identification 
Number
K/2009/19220
K/2009/19220
K/2011/16474
K/2011/16474
K/2011/17931
K/2011/17931
K/2011/24399
K/2011/24399
K/2012/6044
K/2012/6044
K/2011/4769
K/2011/4769
K/2011/14598
K/2011/14598
K/2009/21846
K/2009/21846
K/2009/21846
K/2009/21846
K/2009/23006
K/2009/23006
K/2009/23376
K/2009/23376
K/2009/21845
K/2009/21845
K/2009/21847
K/2009/21847
K/2011/9079
K/2011/9079
K/2011/4393
K/2011/4393
K/2011/6821
K/2011/6821
K/2012/270
K/2012/270
K/2012/11023
K/2012/11023
K/2012/11023
K/2012/11023
K/2012/1731
K/2012/1731
K/2009/23962
K/2009/23962
K/2011/20131
K/2011/20131
K/2011/19397
K/2011/19397
K/2011/21641
K/2011/21641
K/2011/11285
K/2011/11285
K/2012/6246
K/2012/6246
K/2011/13157
K/2011/13157
K/2011/13157
K/2011/13157
K/2012/8613
K/2012/8613
1st	Approach
245
#VALUE!
200
160
#VALUE!
#VALUE!
100
90
0
100
100
120
100
100
#VALUE!
#VALUE!
20
100
80
20
110
#VALUE!
100
100
#VALUE!
#VALUE!
10
20
100
100
#VALUE!
100
120
#VALUE!
#VALUE!
#VALUE!
200
300
90
100
50
0
#VALUE!
#VALUE!
10
#VALUE!
#VALUE!
100
10
0
100
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
0
15
2nd	Approach
190
#VALUE!
190
170
#VALUE!
#VALUE!
120
110
20
100
100
100
105
100
#VALUE!
#VALUE!
40
100
60
100
130
#VALUE!
100
100
#VALUE!
#VALUE!
20
30
100
100
#VALUE!
100
110
0
#VALUE!
#VALUE!
200
300
100
100
20
20
#VALUE!
#VALUE!
20
#VALUE!
#VALUE!
100
10
30
100
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
0
30
Average
217,5
#VALUE!
195
165
#VALUE!
#VALUE!
110
100
10
100
100
110
102,5
100
#VALUE!
#VALUE!
30
100
70
60
120
#VALUE!
100
100
#VALUE!
#VALUE!
15
25
100
100
#VALUE!
100
115
#VALUE!
#VALUE!
#VALUE!
200
300
95
100
35
10
#VALUE!
#VALUE!
15
#VALUE!
#VALUE!
100
10
15
100
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
0
22,5
Pathology 
Identification 
Number
K/2010/22695
K/2010/22695
K/2011/2185
K/2011/2185
K/2011/2185
K/2011/2185
K/2011/13413
K/2011/13413
K/2011/13828
K/2011/13828
K/2011/27000
K/2011/27000
K/2010/1762
K/2010/1762
K/2010/1762
K/2010/1762
K/2010/3341
K/2010/3341
K/2010/17418
K/2010/17418
K/2010/17418
K/2010/17418
K/2009/8889
K/2009/8889
K/2009/14030
K/2009/14030
K/2009/19233
K/2009/19233
K/2011/1098
K/2011/1098
K/2011/1067
K/2011/1067
K/2011/2103
K/2011/2103
K/2010/7337
K/2010/7337
K/2011/2190
K/2011/2190
K/2011/90
K/2011/90
K/2011/550
K/2011/550
K/2011/550
K/2011/550
K/2011/13965
K/2011/13965
K/2011/4074
K/2011/4074
K/2011/10018
K/2011/10018
K/2010/21778
K/2010/21778
K/2011/10460
K/2011/10460
K/2011/12863
K/2011/12863
K/2011/14503
K/2011/14503
K/2011/26249
K/2011/26249
K/2011/26250
K/2011/26250
K/2010/6654
K/2010/6654
K/2010/12286
K/2010/12286
K/2010/17636
K/2010/17636
K/2010/18657
K/2010/18657
K/2010/21779
K/2010/21779
K/2010/22237
K/2010/22237
K/2009/8808
K/2009/8808
K/2012/7719
K/2012/7719
K/2012/27072
K/2012/27072
K/2012/32462
K/2012/32462
K/2012/12648
K/2012/12648
K/2014/18386
K/2014/18386
K/2013/12208
K/2013/12208
K/2012/1800
K/2012/1800
K/2012/8632
K/2012/8632
K/2012/12652
K/2012/12652
K/2012/1021
K/2012/1021
K/2013/17946
K/2013/17946
1st	Approach
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
300
#VALUE!
#VALUE!
200
300
300
270
200
200
#VALUE!
#VALUE!
#VALUE!
#VALUE!
#VALUE!
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Figure	9:	overview	of	the	h-score	in	a	gradient	scale	of	greens	within	the	four	group	of	tissue	samples:	high	risk,	intermediate	and	low	risk,	benign	and	locally	
metastatic	prostate	cancer.	Light	to	darker	equals	0	to	300.	
 
 
34 
 
 
Figure	10:	Overview	of	the	h-score	in	a	gradient	scale	of	greens	within	the	four	group	of	tissue	samples:	tumour,	near	peritumoral,	far	peritumoral	and	
benign.	Light	to	darker	equals	0	to	300.	
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 Figure	11:	A:	TKTL1	score	50.	B:	TKTL1	score	100.	C:	TKTL1	score	200.	D:	TKTL1	score	300	E:	example	of	heterogeneity	of	TKTL1	expression	found	in	tumoural	tissue,	on	the	left	TKTL1	expression	is	higher	than	on	the	right	side	of	the	image	
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3.6 STATISTICAL ANALYSIS 
 
Statistical analysis was performed using R (Version 3.3.2.) for Linux. High and 
low TKTL1 expressing patient groups were compared and the cutoff was 
determined by the midpoint TKTL1 score between M1-stage and M0-stage. 
• Shapiro-Wilk test to determine if data is normally distributed 
• Chi-square test for categorical variables 
• Mann-Whitney U-test to detect differences among the medians of the 
continuous variables 
• Receiver operating characteristics (ROC) analysis for determination of 
cutoff between benign and tumour – Area under the curve (AUC), 
specificity and sensibility 
• Kruskal-Wallis analysis to compare means of three or more samples 
• Post-hoc comparisons of relevant variables were done using Wilcoxon 
with Bonferroni Adjustment for multiple comparisons 
• Spearman's rank correlation coefficient was used a nonparametric 
measure of rank correlation  
 
 
A P value less than 0.05 was considered statistically significant. Results are 
given as median levels (interquartile range). 
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4 RESULTS 
4.1 CLINICOPATHOLOGICAL FINDINGS 
From the initial total number of patients (n=124), 24 were excluded, because of 
insufficient data or tissue artefacts resulting in 100 eligible specimens. The 
median age of patients with prostate cancer was 65 years (61-70). Clinical and 
pathologic characteristics of patients included are shown in Table 7. 
Tumour tissue of 46 patients who underwent prostatectomy, as well as 
corresponding adjacent non-neoplastic prostate tissue, were tested for TKTL1 
expression by immunohistochemistry. They had a median age of 64 (61-68) and 
none of them had metastasis at time of surgery. The predominant pathological 
T-classification was pT2c (63.04%), while pT3a was the second most common 
(21.74%) and only 2.17% had pathological involvement of lymph nodes. The 
most common Gleason score were 6 and 9 (23.91%). Histologically, all tumours 
were conventional acinar adenocarcinomas.  
 
22 patients were included as controls. These had undergone TURP, 
transvesical prostatic adenomectomy and radical cystectomies. Age range 
predominance was between 65 and 85 (86.36%), with median age of 71 years 
(67-77). 
 
A total of 32 patients with metastatic prostate cancer were also included. 
90.63% of these patients were older or equal to 65 years, the median age being 
73 years (71-73). The TMN classification given to this group is a clinical 
parameter, in contrast to patients who underwent prostatectomy, which are 
classified according to pathological criteria. 43.75% had no T-stage information, 
40.63% had no clinical N-stage, and 3.12% had no M-stage.  
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Total patients 100    
Age median (IQR) 66 (62-70)   
i. Benign 22   
Age    
<65 3 (13.64%)   
65-85 19 (86.36%)   
>85 0   
ii. RP-PCa 46 iii. TURP- PCa  32 
Age  Age  
<65 23 (50%) <65 3 (9.38%) 
65-85 23 (50%) 65-85 28 (87.5%) 
>85 0 >85 1 (3.13%) 
T stage  T stage  
T1 0 T1 0 
T2a  4 (8.70%) T2a 0 
T2b 0 T2b 0 
T2c 29 (63.04%) T2c 1 (3.13%) 
T3a  10 (21.74%) T3a  1 (3.13%) 
T3b  3 (6.52%) T3b  4 (12.5%) 
T4 0 T4 12 (37.5%) 
Unknown 0 Unknown 14 (43.75%) 
Metastases  Metastases  
M0 46 (100%) M0 0  
M1 0 M1 31  (96,88%) 
Unknown 0 Unknown 1 (3.12%) 
Lymph node stage  Lymph node stage  
N0 44 (95.65%) N0 2 (6.25%)  
N1 1 (2.17%) N1 17 (53.13%) 
Unknown 1 (2.17%) Unknown  13 (40.63%) 
Gleason score  Gleason score  
6 11 (23.91%) 6 0 
7a 8 (17.39%) 7a 2 (6.25%) 
7b 5 (10.87%) 7b 1 (3.13%) 
8 10 (21.74%) 8 2 (6.25%) 
9 11 (23.91%) 9 21 (65.63%) 
10 1 (2.17%) 10 3 (9.38%) 
Unknown  Unknown 3 (9.38%) 
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 Table	 7:	 Clinicopathological	 findings	 of	 the	 study	 population.	 Benign	 group	 include:	 26	 benign	specimens	 from	 patients.	 RP-PCa	 group:	 46	 radical	 prostatectomy	 specimens	 from	 men	 with	clinically	 detected	 PCa	 and	 the	 TUR-P	 PCa	 group:	 32	 TURPs	 specimens	 from	 patients	 with	obstructive	urinary	disorder	with	metastatic	PCa.	
 
 
4.2 TKTL1 EXPRESSIONS SCORES 
 
The TKTL1 scores from all tissues were not normally distributed (p<0.001). For 
these reason non-parameteric tests were used to test for differences between 
groups.  
 
4.3 TKTL1 EXPRESSION IN BENIGN TISSUE AND PROSTATE CANCER 
Figure 12 shows the staining intensity of TKTL1 in normal and tumoral prostatic 
tissue (from all patients with diagnosed prostate cancer, including those with 
metastatic disease). In our study the TKTL1 staining was cytoplasmatic. The 
mean TKTL1 expression score in benign tissue was 100 (57.5 - 105), while the 
mean TKTL1 expression score in tumour tissue was 243.13 (187.04 - 295). 
TKTL1 expression was significantly higher in tumour tissue in comparison with 
normal tissue (p<0.001). 
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ROC analysis was used to determine how accurately TKTL1 expression could 
discriminate between cancer and benign, as well as to calculate a sane value 
that would serve as a cutoff, separating the two groups.  We found 125 to be 
the best value for this purpose with AUC=92.42%, 95% CI [85.94%–98.9%] with 
86.36% specificity and 92.30% sensitivity (see Figures 13 and 14).  
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Figure	12:	Comparison	between	TKTL1	expression	in	benign	and	tumoral	tissue	
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Figure	13:	Receiver-operating	characteristic	curve	for	TKTL1	as	immunohistochemical	marker.	
Figure	14:	Violin	plots	of	TKTL1	expression	in	benign	tissue	samples	and	tumour	samples.	Black	lines	represent	cutoff	(125)	between	benign	and	tumour,	coloured	lines	are	density	plots	of	data	distribution.		
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4.3.1 TKTL1 EXPRESSION IN PERITUMORAL NON-NEOPLASTIC TISSUE AND 
PROSTATE CANCER 
 
Figure 15 shows the staining intensity of TKTL1 in benign tissue, peritumoral 
non-neoplastic tissue and prostate cancer in patients who underwent 
prostatectomy. The results show peritumoral non-neoplastic tissue had a lower 
TKTL1 staining intensity than in tumoral tissue (135.42 (100-195.16) compared 
with 200 (172.19-254.38), p<0.0001). Compared to benign tissue, TKTL1 
staining intensity of peritumoral non-neoplastic tissue was higher (135.42 (100-
195.16) compared with 100 (57.5, 105), p=0.0006). In summary, there is a 
positive progression of TKTL1 concentration from benign, to peritumoral to 
tumoral tissue. 
 
 Figure	15:	Comparison	between	TKTL1	expression	in	benign,	peritumoral	and	tumoral	tissue	from	patients	who	underwent	prostatectomy.	
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4.3.2 TKTL1 EXPRESSION IN FAR, NEAR PERITUMORAL TISSUE AND TUMORAL 
TISSUE 
 
Figure 16 shows the staining intensity of TKTL1 in peritumoral non-neoplastic 
tissue far, near and prostate cancer in patients who underwent prostatectomy. 
The results show no difference between far peritumoral non-neoplastic tissue 
TKTL1 staining intensity and near peritumoral non-neoplastic tissue (123.75 
(100-195.16) compared with 156.88 (100-195.16), p=0.4625). In summary, a 
progression of TKTL1 concentration from far peritumoral to near peritumoral 
was not detected.  
 
 Figure	 16:	 Comparison	 between	 TKTL1	 expression	 in	 far	 peritumoral,	 near	 peritumoral	 and	tumoral	tissue,	from	patients	who	underwent	prostatectomy.	
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4.4 TKTL1 EXPRESSION IN METASTATIC AND NON-METASTATIC PROSTATE 
CANCER 
 
Regarding M-stage, patients with metastatic prostate cancer had a significantly 
higher TKTL1 expression than those with non-metastatic disease (200 (172.19-
254.38) compared with 300 (222.50-300), p<0.0001, see also Figure 17). 
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Figure	17:	Comparison	between	TKTL11	expression	in	non-metastatic	and	metastatic	prostate	cancer.	
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4.5 TKTL1 EXPRESSION AND HORMONE SENSITIVITY 
 
We found no difference in TKTL1 expression between hormone refractory and 
hormone sensitive prostate cancer in patients with metastatic prostate cancer 
who underwent palliative TURP (300 (215.63-300) compared with 296.25 
(248.75-300), p=0.9015) (see Figure 18). 
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Figure	18:	Comparison	between	TKTL1	expression	in	hormone	sensitive	prostate	cancer	and	hormone	refractory	prostate	cancer	in	patients	who	underwent	TURP.	
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4.6 TKTL1 EXPRESSION AND GLEASON SCORE 
 
A comparison within the group of all patients with prostate cancer regarding the 
Gleason score was also performed. Here, we decided to compare the tissues 
from patients with a Gleason score ≥ 8 and < 8 (see Figure 19). We found a 
significant difference between the two groups, being the expression of TKTL1 
found higher within the group of patients with a Gleason score ≥ to 8 (261.25 
(200-300) compared with 187.50 (158.75-237.50), p<0.001). 
 
 Figure	19:	Comparison	between	TKTL1	expression	when	Gleason	Score	≥	 	8	or	<	8	 in	all	patients	with	prostate	cancer.	
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Results obtained using Kruskal-Wallis test indicated some differences in 
Gleason score and TKTL1 expression in all patients with prostate cancer χ2(5) 
=19.25, p=0.0017 (see Figure 20). Post-hoc comparisons revealed a significant 
difference between Gleason scores 6 and 9 (p=0.0047), all other pairwise 
comparisons had p>0.1011.   
 
 Figure	20:	Comparison	between	TKTL1	expression	in	different	Gleason	Scores	in	all	patients	with	prostate	cancer.	
 
 
We also compared tissues from patients who underwent prostatectomy with a 
Gleason score ≥ 8 and < 8 (see Figure 21). We found no significant difference 
between the two groups (212.50 (187.50-254.38) compared to 195.00 (161.88-
246.88), p=0.3384).  
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 Figure	21:	Comparison	between	TKTL11	expression	when	Gleason	Score	≥		8	or	<	8	in	patients	who	underwent	prostatectomy.	
 
 
 
4.7 TKTL1 EXPRESSION AND PATHOLOGICAL T-STAGE 
 
A comparison within the group of patients with prostate cancer who underwent 
radical prostatectomy regarding the pathological T-stage was also performed. 
Here, we decided to compare the TKTL1 expression from patients with a lower 
and equal pT2 (organ-confined) and higher than pT2 (locally advanced). We did 
not find a significant difference between the two groups; the expression of 
TKTL1 was similar within both groups (200 (165-242.5) compared with 243.75 
(197.5-286.5), p=0.0537, Figure 22). 
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 Figure	22:	Comparison	between	TKTL1	expression	in	T-stage	≤	2	and	T-stage	>	2.	
 
 
 
 
Kruskal-Wallis test was performed and pT-stage 2a – 3b failed to predict TKTL1 
expression in all patients who underwent radical prostatectomy χ2(3) =5.61, 
p=0.132 (see Figure 23). 
Post-hoc comparisons revealed no significant difference between T-stages (all 
p > 0.23). 
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 Figure	23:	Comparison	between	TKTL1	expressions	in	different	T-stages.	No	patient	was	classified	with	stage	T2b.	
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4.8 TKTL1 EXPRESSION AND DISEASE PROGRESSION 
 
A significant difference is seen between the following four groups of tissues: 
benign, peritumoral, non-metastatic tumor tissue and metastatic tumoral tissue 
(see Figure 24 and Table 9) 
 
 
 
 
 Figure	24:	TKTL1	expression	in	progression	of	disease,	from	benign	through	peritumoral	and	non-metastatic	PCa	to	metastatic	PCa.	
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4.9 PSA CONCENTRATION AND TKTL1 EXPRESSION 
 
The median PSA concentration of the total number of patients was 7.4 ng/ml. 
These levels did not significantly correlate with TKTL1 expression (Spearman´s 
ρ= 0.18, p=0.0847, Figure 25). 
 
 Figure	25:	PSA	concentration	plotted	against	TKTL1	expression	in	all	patients.	To	aid	visualization,	PSA	values	above	300	ng/ml	were	excluded.	
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4.10 AGE AND TKTL1 EXPRESSION 
 
The median age of the total number of patients was 66 (62-70). A correlation 
between TKTL1 expression and age was not found in all patients (Spearman´s 
ρ= 0.09, p=0.3911, Figure 26).  
 
 
 
 Figure	26:	Age	plotted	against	TKTL1	expression	in	all	patients.	
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4.11 TKTL1 EXPRESSION AND CLINICOPATHOLOGICAL PARAMETERS 
 
All patients with PCa were split into two groups, into low and high, based on 
whether a patient’s TKTL1 expression score was below or above the midpoint 
between the mean of non-metastatic and metastatic PCa. Patients in both 
groups were compared across several clinicopathological parameters (see 
Table 8). We found a significant difference between low and high TKTL1 
expressing groups regarding T-stage, M-stage, N-stage and Gleason score. 
Age groups differences were non-significant in these two expression groups. 
 
In order to simplify all above statistical analysis a summary was compiled in a 
table (see Table 9). 
 
 
 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
  Low expression High expression p-value 
     
Age    0.1565 
<65  16 (20.51 %) 11 (14.10 %)  
≥65  21 (26.92 %) 30 (38.46 %)  
     
T-stage    0.0027 
T1+T2  23 (29.49 %) 11 (14.10 %)  
T3+T4  14 (17.95 %) 30 (38.46 %)  
     
Metastases*    0.0023 
M0  29 (37.66 %) 17 (22.08 %)  
M1  8 (10.39 %) 23 (29.87 %)  
     
Lymph-node stage*    0.0257 
N0  28 (43.75 %) 18 (28.13 %)  
N1  5 (7.81 %) 13 (20.31 %)  
     
Gleason score*    0.0075 
6  10 (13.33 %) 1 (1.33 %)  
7a  7 (9.33 %) 3 (4.00 %)  
7b  3 (4.00 %) 3 (4.00 %)  
8  6 (8.00 %) 6 (8.00 %)  
9  10 (13.33 %) 22 (29.33 %)  
10  1 (1.33 %) 3 (4.00 %)  
     Table	 8:	 Correlation	 of	 TKTL1	 expression	 and	 clinicopathological	 features	 (both	 clinical	 and	pathological	TNM	findings)	 in	78	prostate	cancer	cases.	 *One	patient	has	no	M-stage,	14	have	no	N-stage	and	3	without	Gleason	score.	
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 Benign Tumoral tissue p-value 
TKTL1 score 100 (57.5-105) 243.13 (187.04-295) < 0.001 
 
 Benign Peritumoral* p-value 
TKTL1 score 100 (57.5-105) 135.42 (100-195.16) 0.006 
 
 Peritumoral* Tumoral tissue*    p-value 
TKTL1 score 135.42 (100-195.16) 200 (172.19-254.38) <0.0001 
 
 Far peritumoral tissue* Near peritumoral tissue* p-value 
TKTL1 score 123.75 (100-195.16) 156.88 (100-195.16) 0.4625 
 
 Metastatic Non-metastatic p-value 
TKTL1 score 300 (222.50-300) 200 (172.19-254.38) <0.0001 
 
 Hormone-Refractory Hormone-Sensitive p-value 
TKTL1 score 300 (215.63-300) 296.25 (248.75-300) 0.9015 
 
 Gleason score < 8 Gleason score ≥8 p-value 
TKTL1 score 187.50 (158.75-237.50) 261.25 (200-300) <0.001 
 
 T-Stage  ≤ 2* T-Stage > 2* p-value 
TKTL1 score 200 (165-242.5) 243.75 (197.5-286.5) 0.0537 	Table	9:	Median	TKTL1	levels	among	all	patients,	median	(interquartile	range).	P-values	from	Mann-Whitney	U-Tests.	*Tumor	tissues	from	specimens	obtain	only	from	prostatectomies.	
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5 DISCUSSION 
 
5.1 OVERVIEW OF DISCUSSION 
An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 
2012 [1]. The rate of prostate cancer incidence increased greatly in the 1990s, 
then became stable over the last decade, possibly due to introduction of ready 
PSA testing.  
 
However, men's life expectancy has generally increased. Since age is a well-
known risk factor for prostate cancer, it is presumed that the economic burden 
will also increase over the years, unless new diagnostic, prognostic and 
therapeutic tools are discovered. In 2010, the total cost of handling prostate 
cancer (diagnosis, treatment and 5 year follow-up) was 567.906.109 Euros in 
Germany – 12,794 euros per patient [129]. 
 
Current diagnostic tools for detecting and screening prostate cancer include 
PSA and digital rectal examination. DRE should always accompany the PSA-
test when performing an early diagnosis. A multicenter clinical trial comparing 
DRE and PSA serum in the early detection of prostate cancer revealed a PCa 
detection rate of 3.2% for digital rectal examination, 4.6% for PSA and 5.8% for 
the 2 methods combined, with a positive predictive value of 32% for PSA and 
21% for DRE [130].  
When prostate cancer is suspected, a prostatic biopsy -- conventionally, a 12-
core transrectal ultrasound-guided biopsy – should be performed to diagnose 
prostate cancer [9]. When the diagnosis is made, we should have the PSA-
values, the Gleason score (acquired though prostate biopsy) and the T-staging 
(through DRE or transrectal ultrasound). The clinical staging may be further 
extended when a suspicion of extraprostatic, locally advanced, or metastatic 
disease is present, including a pelvic MRI-staging and bone scan. These and 
clinical findings are the current preoperative parameters used by 
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urologists/oncologists for determining treatment options in patients with newly 
diagnosed prostate cancer. 
If a surgical approach is chosen, a radical prostatectomy may be offered, 
involving complete removal of prostate, seminal vesicles, part of the urethra, 
and the surrounding lymph nodes. After surgery, the histological findings are 
analyzed and used as prognostic factors, together with the preoperative 
findings. These factors are used clinically on a daily basis to better monitor the 
patient and promptly intervene when recurrence is detected.  
 
However, current diagnostic, predictive and prognostic parameters are still not 
so accurate, showing a need to explore other molecular biomarkers, to better 
predict the outcomes and prognoses of treated and untreated patients. 
 
To better understand the progression of prostate cancer, TKTL1 expression 
was evaluated to determine its usefulness in detecting certain outcomes 
including disease aggression. 
 
5.2 CURRENT TOOLS IN PROSTATE CANCER – PREOPERATIVE FINDINGS 
Cancer screening programs are not universally accepted and there is no 
worldwide consensus that benefits outweigh the risks. A review from 2013 
involving 5 randomized clinical trials (RCTs, including 341,342 men) concluded 
prostate cancer screening did not significantly decrease prostate cancer-
specific mortality, though any reduction in prostate cancer-specific mortality may 
take up to 10 years to accrue.  Overdiagnosis and overtreatment are common 
and are associated with treatment-related harm [131]. In other words, treatment 
offered to patients who would not have developed clinically relevant prostate 
cancer leads to unnecessary complications and side effects [132,133].  
Later on, various studies attempted to evaluate whether PSA reduces prostate 
cancer mortality rates and those results remain controversial. The latest large 
randomized study performed by a European Randomized Study of Screening 
for Prostate Cancer (ERSPC) in 2014 showed substantial reduction in prostate 
cancer mortality attributable to PSA testing [134].  
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PSA-testing was originally approved by the FDA in 1986 to monitor the 
progression of prostate cancer and is still considered the gold-standard test for 
that purpose. And years later has been employed as a screening tool also. 
 
As a screening tool, the PSA test has its own limitations and pitfalls, including 
false positive outcomes where there is an overlap in the serum PSA levels 
among men with cancer and those with benign disease, so is not disease-
specific. In the absence of better tools, PSA is still useful, but lacking, so a great 
deal of effort is being devoted to improve its performance. Examples are the 
free PSA and the PSA density, detected by dividing the serum PSA level by the 
prostate volume detected by TRUS. The higher the density, the more likely it is 
to find a positive prostate biopsy. Prostate Health Index (PHI) is a recently 
approved diagnostic blood test, which uses a formula combining total PSA, free 
PSA and p2PSA (a PSA isoform found in peripheral blood). Patients with high 
total PSA and p2PSA and low free PSA are more likely to present with prostate 
cancer at clinically significant levels [135,136]. A meta-analysis from 2014, 
analyzing 7 studies, showed PHI had a specificity of 0.88 (95% CI, 0.82–0.92) 
and sensitivity of 0.74 (95% CI, 0.66–0.81) for prostate cancer detection [137]. 
 
Additionally, a transrectal ultrasound can be performed and is considered the 
procedure of first choice for prostate imaging. It should be noted that TRUS has 
poor accuracy in prostate cancer detection and staging [138].  
 
Multiparametric magnetic resonance imaging, combining the morphological 
assessment of T2-weighted imaging with diffusion-weighted imaging is a tool 
used ever more frequently to help detect prostate cancer [139,140].  
 
Despite significant progress in early detection, the majority of prostate cancers 
detected at early stages come with uncertain prognoses. This explains 
increasing efforts to discover and develop better clinical tools to monitor and 
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detect earlier recurrence, predict treatment response, and better understand the 
course of disease progression.  
5.2.1 PROGNOSTIC PARAMETERS IN PROSTATE CANCER 
48 radical prostatectomy specimens were obtained from male patients in this 
study, who underwent a curative surgical approach. 
 
The prognostic tools used in standard practice include the pre- and post-
operative PSA levels, [141–143] histological grade of tumour- Gleason score 
[16,144], histological subtype, TNM [145], performance status, [146,147] age 
[148,149], serum acid phosphate levels [150,151] and surgical margin [145].  
These are the current parameters used to prognosticate the disease outcome 
following treatment and to predict biochemical recurrence.  
 
The College of American Pathologists published a Consensus Statement in 
1999 categorizing prognostic factors into three groups: Category I included 
proven and useful prognostic factors, Category II included promising factors, 
which were extensively studied, but not yet proven to be statistically significant, 
and Category III included factors that have not reached prognostic value. [145] 
 
From the group of patients who underwent radical prostatectomies, we could 
retrieve all Category I parameters, including PSA-values, pathologic stage, 
Gleason score, and surgical margin.  
 
The median preoperative PSA-value from patients who underwent radical 
prostatectomies was 6.93 (4.8-11.1). The most frequent pathological stage 
found was pT2c. Since radical prostatectomy has a curative intent, it was 
expected to find in this group of patients a pathological stage corresponding to a 
confined prostate cancer. All patient cancers were non-metastatic, as 
metastasis would contraindicate a radical prostatectomy. The most commonly 
found Gleason score were 6 and 9.  
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Research into biomarkers has exploded over the last decades. Some examples 
include prognostic factors/markers, only used in some centers, include Ki-69 
(MIB-1), cell cycle markers (p27, p21, p43), DNA ploidy, p53, bcl-2, ELISA to 
human glandular kalikrein 2, and AMACR [152].  
An abundance of other markers, used currently only in the research field, might 
be applied in clinical practice to better understand prostate cancer, especially its 
progression.  
 
In the last decade some oncogenic signaling pathways and proteins, classically 
presented as regulators of cell division, revealed to have a link with glucose 
metabolism leading to aberrant metabolic programming. One example of a 
protein, which is associated with glucose reprogramming in oncogenesis is 
TKTL1. An existence of studies involving prostate cancer and TKTL1 
immunostaining has, as of yet, not been found. 
 
5.3 TKTL1 PROTEIN 
The TKTL1 protein regulates and sustains the metabolic needs of the cells, 
playing a pivotal role as a reversible link between PPP and glycolysis, switching 
flux to meet cellular metabolic needs. Alterations in energy flow help the 
malignant cell to maintain its characteristics and to improve cell survival, 
proliferation and progression in a process called metabolic reprogramming. For 
these reasons, cancer cell metabolism is an area of great current interest to 
researchers [153].  
A 2010 study found a close link between lactate dehydrogenase (LDH) 
isoenzymes (enzymes which catalyze pyruvate into lactate) and TKTL1 
expression. This could indicate that TKTL1 is involved in glucose metabolism 
reprogramming, as mentioned above [154]. Another interesting study revealed a 
slowed cell growth, glucose consumption and lactate production in malignant 
cells (colon carcinoma cells) after TKTL1 suppression, revealing the importance 
of TKTL1 activity in the tumorigenesis process within some cancer cells [89].  
The presence of an overexpression/upregulation of TKTL1 has been found in 
multiple cancers, including oral squamous cell carcinoma [155], rectal cancer 
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[156], gastric cancer [157], serous papillary ovarian adenocarcinomas [99], 
human endometrial cancer [158], renal cell cancer [100] and papillary thyroid 
carcinoma [159]. And in gene-silencing TKTL1 studies, cancer proliferation was 
significantly decreased in human hepatoma cell line [106] and human gastric 
cancer cells in vitro and in vivo [160]. 
 
Prior studies suggest TKTL1 may be indispensable in tumorigenesis. Through 
the PPP two major products are produced, ribose and NADPH, which will help 
to maintain an oxidative homeostasis; a high TKTL1 activity will also maximize 
the production of antioxidants and macromolecules, including nucleotides.  
 
5.4 TKTL1 AND PROSTATE CANCER 
To our knowledge, few studies have explored the association between 
variations in TKTL1 expression (in immunohistochemistry) in prostate cancer. 
Published studies looking into the relationship between TKTL1 and prostate 
cancer involved only the EDIM-TKTL1 test which presented contradictory 
results [109,161,162]. Grimm et al. showed EDIM-TKTL1 (with EDIM-Apo10, 
another marker under study) were highly sensitive and specific for detecting 
patients with prostate cancer, where 105 of 115 patients with prostate cancer 
showed positive EDIM-TKTL1 results [155]. 
 
A 2016 study involving prostate cancer patients revealed no correlation 
between serum TKTL1 (using Enzyme-linked immunosorbent assay, ELISA 
methods) with clinicopathological findings. This conclusion opposes prior 
studies using EDIM-TKTL1 test blood [162].  
 
 
 
5.5 TKTL1 EXPRESSION - BENIGN VS PROSTATE CANCER  
TKTL1 expression levels were firstly compared between benign and tumour 
tissue, revealing a significant difference. Benign tissue was retrieved from 
patients who underwent TURP, transvesical prostatic adenomectomy and 
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radical cystectomy. Concomitantly, although an open surgery has its own risk, 
an advantage compared to TURP is the prevention of TURP syndrome, a life-
threatening condition where absorption of irrigation fluid during TURP leads to a 
hyponatremia. 
 
Since TKTL1 is a relative new marker, a validated threshold has not yet been 
established, and neither has a scoring system. In the present work, the cutoff 
for benign vs. cancer was first determined using ROC analysis, a method 
commonly used in other medical areas and starting to be adopted by studies 
using IHC [163–165]. This was done as a first step, because we believe the 
ability to safely differentiate benign and cancer patients to be paramount.  
Afterwards, we tried to establish an adequate expression cutoff level that would 
differentiate patients with low and high TKTL1 concentration, in order to 
evaluate whether any clinicopathological characteristics are related to different 
degrees of protein expression. Unfortunately, this is not an easy task, because 
depending on the chosen outcome for the ROC analysis (N-stage, M-stage, 
Gleason score e.g.), the resulting groups will contain a different amount of 
patients. Taking into account current practices in published studies, we decided 
against using a clinical variable such as M- or N-staging as the defining 
characteristic for the cutoff. Instead, we began by using ROC analysis to find a 
TKTL1 expression cutoff that would safely separate benign tissue from tumour.  
This border was found to be a score of 125, with additional visual confirmation 
from plots. The cutoff from high to low TKTL1 expression was the midpoint 
TKTL1 score between M1-stage and M0-stage, which was 233. The validity and 
reproducibility of such approach could be debatable but, as mentioned above, 
it’s the current practice in well regarded studies [166–171]. 
 
 
 
5.6 TKTL1 EXPRESSION IN RADICAL PROSTATECTOMY SPECIMENS 
Among our cases, the median age of men with prostate cancer (who underwent 
prostatectomy) was 64 —not far from the expected age at diagnosis in patients 
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fit for surgery. A similar median age was reported in a study from Denmark, 
which included 1350 patients who underwent radical prostatectomy. The 
median age at surgery in this study was 63 years [172]. 
 In Germany most tumours are discovered in the early T-stages (T1 and T2) 
[173]. In our cohort, 71.74% had a T-stage equal or less than T2. 
 
From each radical prostatectomy specimen, we retrieved around 8-12 cores, 
grouped in 3 classes: far peritumoral, near peritumoral and tumour tissues.  
 
Here, we found a significant difference between peritumoral (non-neoplastic) 
prostate tissue and prostate cancer, with a higher TKTL1 expression being 
found in tumoral tissue. The median TKTL1 score in peritumoral tissue was 
lower than in the tumour, but not lower than 125, the cutoff found between 
benign and cancer. 
Presumably, the pre-tumorigenesis process had already begun in the 
peritumoral prostatic tissue, even though it was classified as non-malignant due 
to lack of observable architectural changes, potentially pointing out that 
molecular changes of cancerogenesis occur prior to the change of histological 
architecture. Ultimately, we believe the surrounding non-malignant tissue had 
initiated glucose metabolism alterations, in order to maintain and provide the 
required needs of a malignant cell, thus in order to maintaining a high metabolic 
rate and suppressing the potentially prejudicial effects of reactive oxygen 
species, improving survival against oxidative stress  [174].  
 
Interestingly, a significant difference was also found between the peritumoral 
tissue and benign tissue (with BPH). Revealing a positive progression of TKTL1 
concentration from benign, to peritumoral to tumoral tissue. It could then be 
argued that, in peritumoral tissue, the altered metabolic alterations (present in 
cancer cells) had already begun, even though no morphological change could 
be found—it is likely that these cells had not yet accumulated enough changes 
to be reflected in the cellular architecture / morphology, which the Gleason 
score classification is based on.  
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Taking these results together, the significant difference between benign, 
peritumoral and tumoral tissue, shows a general trend of increased TKTL1 
expression with disease progression from benign to malignant tissue. 
Tentatively, this could be extrapolated to imply that the glycolytic metabolism 
alteration, specifically the shift from the oxidative phosphorylation pathway into 
aerobic glycolysis, is not so much an on/off switch, but a fluid progression 
(potentially parallel to other oncological pathways and reversible) that follows 
tumorigenesis.  
 
 
5.7 TKTL1 EXPRESSION IN METASTATIC PROSTATE CANCER 
As one of the aims of the study was to evaluate the progression of expression 
of TKTL1 in the disease progression of prostate cancer, we also included 
patients with metastatic PCa to better evaluate the TKTL1 expression in 
advanced or metastatic prostate cancer, the final stages of disease progression. 
Since in this group of patients a radical prostatectomy is not recommended, 
tissue samples were retrieved from patients who underwent palliative TURP. 
 
Comparing the TKTL1 expression between this group of patients and patients 
who underwent radical prostatectomy showed a significant difference, TKTL1 
being expressed higher in the group of patients who underwent palliative TURP.  
 
Further analysis showed a significant difference between TKTL1 expression in 
patients with metastatic and non-metastatic prostate cancer, being found in 
lower expression in the latter group. Presumably, TKTL1 expression arises with 
tumour activity or volume. 
 
Still analyzing the tissues of this group of patients, no difference was found 
between TKTL1 expressions in tissues from patients with hormone-sensitive or 
hormone-refractory prostate cancer.  Perchance the mechanism of change from 
hormone-sensitive to refractory does not involve a change in the metabolism of 
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glucose solely. The growth of tumoral cells that have adapted to a castration 
environment, in order words, in low levels of androgens, is a complex 
mechanism, which is thought to be associated with androgen receptor pathway 
distortion [175–177].    
 
5.8 TKTL1 EXPRESSION AND CLINICOPATHOLOGICAL FINDINGS  
The construction for the clinicopathological correlation analysis was not an easy 
task due to the existence of two heterogeneous group of patients. One, in which 
the operation (radical prostatectomy) had curative intent, while the other group 
undergone a TURP, with palliative intent to relieve urinary obstructive 
symptoms. So the acquired clinical information is different in both groups, 
including the TMN classification. This means that the patients who underwent 
prostatectomy where classified based on a pathological report (pTNM), while 
the palliative patients had a clinical TNM (cTNM), based on clinical findings. 
Still, we believe both groups must be included in the analysis, since they 
represent different disease stages. 
 
The results showed a correlation between high and low TKTL1 expression and 
M-stage, N-stage, T-stage and Gleason score. 
When analyzing the data comparing the clinicopathological findings with a 
continuous TKTL1 levels such findings were not observed. The division in two 
groups (high and low TKTL1 expression) was determined by using a cutoff of 
233.52, which is the midpoint between mean TKTL1 values of M1 and M0.  
 
An association was found between higher Gleason scores and high TKTL1 
expression. A phenomenon that is not yet understood, with further studies 
definitely encouraged; studies with a specific design aiming to understand the 
interaction of TKTL1 expression and aggressiveness of disease. There are no 
registered studies evaluating TKTL1 expression and Gleason score. 
A progression of TKTL1 expression with Gleason score would be expected, 
because since morphological changes presumably arise from cytological 
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alterations, the more architectural distortion, the more intrinsic alterations 
should be found.  
 
An association was also found between high TKTL1 expression and higher T-
stages. When analyzing the TKTL1 expression between ≤ T2-stage (organ-
confined disease) and >T2-stages a significant difference was found. The same 
result was achieved when comparing M1-stage to M0-stage, and N1-stage to 
N0-stage. Presumably a higher TKTL1 expression may be found to correlate 
with tumor load or activity, in other words, with higher numbers of cancer cells, 
increased size of a tumor, or with increased amount of cancer in the body. 
Higher TKTL1 values are significantly associated with more advanced disease 
stages. There was no correlation found with age nor PSA levels.  
 
Although interesting results were found from the clinicopathological correlation 
analysis, it does not allow for definitive conclusions to be drawn. For that 
purpose, a follow-up study should include more patients in homogeneous 
groups. A longitudinal study following patients from the first diagnosis onwards, 
while logistically more complex, would pinpoint when the metabolic alterations 
start and better chronologically separate the TKTL1 increase and eventually 
determine outcomes. 
 
This study has shown us that a dysregulation of metabolism may be integrated 
in the tumorigenesis of prostate cancer. The process of transformation to a 
more malignant cell, may involve a metabolic shift of flux or an imbalanced 
energy production not through a mitochondrial oxygen-dependent ATP 
production instead in aerobic glucose degradation. The overexpression of 
TKTL1 found in prostatic cancer cells support a finding of increased flux in the 
PPP, especially in metastatic prostatic cancer cells.  
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5.9 IMMUNOHISTOCHEMISTRY- PITFALLS 
 
The prostate cancer diagnostic grading system is based on architectural 
organization and morphological characteristics of H&E stained prostatic tissue. 
In prostate cancer research numerous potential biomarkers are currently under 
study, some in the field of immunohistochemistry. Similar to Gleason score, 
immunohistochemistry has intra-observer and inter-observer variability [178–
181]. Although this method has its limitations, including pre-analytical variability 
(fixation, antigen retrieval, incubation, endogenous peroxidase block, staining, 
counterstaining, mounting) and subjective interpretation and scoring systems, it 
still is a technique often used to help discriminate benign from malignant tissue, 
confirm the origin of poorly-differentiated carcinoma, subtyping carcinomas, and 
providing prognostic and therapeutic information [178]. 
Besides taking into account factors such as temperature, incubation time, 
fixation type, materials and control samples, interpretation and scoring will also 
play an important role when dealing with outcomes from studies using IHC.  
Although immunohistochemistry has its limits, it’s still a very important 
technique, already integrated in current diagnostic algorithms for cancers, 
including HER2 protein in breast cancer and HER2 in gastric cancer [116,182] .  
In prostate cancer, immunohistochemistry is also applied to distinguish primary 
adenocarcinoma of the prostate from secondary tumours, using PSA, PSMA 
(prostate-specific membrane antigen), AR (androgen receptor), ERG (Ets-
related gene product), Prostein (P501s), NKX3.1 (homeobox protein NKX3.1)   
[122,183,184]. 
 
Most studies use a semi-quantitative approach to determine expression, 
involving a visual scoring system.  A major problem, that will aggravate with 
time due to increase number of IHC studies, are the contradictory results in 
literature and incompatibility to compare results due to lack of conformity in 
interpretation of IHC expression. Attempts are being made to find a better 
solution to interpret the staining, including automated IHC measurements 
involving software algorithms and whole-slide imaging systems. Studies have 
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shown that digital image analysis was superior to visual score in detecting 
differences within tissues [185,186]. 
 
TMA slides were reviewed two times. Estimating intensity of stain and extent is 
a common method used as a visual scoring system. However, estimation of 
extent in some tissue may not be an ease. The distribution / extension of a 
protein expression is usually not bimodal, the staining of cancer cells is 
heterogeneous and it displays a continuous range of staining intensities, being 
difficult to estimate the exact staining intensity as also the extent of each 
staining score. Which resulted in multiple cluster of TKTL1 expression H-scores, 
the impact of these cluster effect in the study was not determined. 
 
Another limitation often found when working with immunohistochemistry is the 
determination of the cutoff score. In studies using novel markers in 
immunohistochemistry, a cutoff score is often determined arbitrarily—negative 
and positive, low and high. The method used to determine cutoff score varies in 
different studies. The cutoff between prostate cancer and benign was 
determined by ROC analysis. The cutoff from high to low TKTL1 expression 
was the midpoint TKTL1 score between M1-stage and M0-stage. 
 
Secondly, in order to minimize pre-analytical variability, the TMA construction as 
also the staining process was performed by the same person, an expertise in 
the field of immunohistochemistry. Concerning the method of interpretation, a 
suggestion of future study would be to review and analyze again the data using 
an automated IHC measuring system, and compare it with the current data. 
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5.10 FUTURE DIRECTIONS 
5.10.1 TKTL1 AS A DIAGNOSTIC BIOMARKER 
An interesting result when comparing benign, non-malignant peritumoral and 
prostate cancer was revealed. TKTL1 expression in non-malignant peritumoral 
tissue was lower than in tumoral tissue and higher than in benign tissue.  
From this finding we could extrapolate that glycolytic metabolism alteration is a 
fluid process following the tumorigenic transformation. TKTL1 expression 
reflects an intrinsic process of metabolomic reprogramming and therefore is not 
detectable through the diagnostic criteria of the Gleason score, since this 
classification is only based on morphological alterations.  This means that, 
when analyzing these peritumoral tissues, they will be classified as non-tumoral, 
in spite of a tumorigenesis process that might have already begun. 
What can this finding bring to the clinical practice? 
The clinical diagnostic tools used to detect prostate cancer are, classically, the 
PSA-value, digital rectal test and biopsy (as imaging tests, we could include the 
transrectal ultrasound of the prostate and the multiparametric MRT-Prostate). 
Elevated PSA is a common indication for prostate biopsy, and due to the pitfalls 
associated with this marker, many biopsied patients with elevated PSA will yield 
a negative result for malignancy. This situation creates anxiety for the patient 
and the urologist, because the follow-up of this group of patients, and also the 
decision to re-biopsy, is never taken lightly.    
Since TKTL1 expression is different in non-malignant peritumoral and in benign 
tissue, further research should be pursued in order to find if TKTL1 expression 
could help in patients with elevated PSA and prior negative biopsies to 
differentiate BPH from potentially pre-malignant process, helping the urologist to 
offer an adequate follow-up (more rigorous monitoring) and decide if a re-biopsy 
is needed, and if needed, when.  
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5.10.2 TKTL1 AS A PREDICTIVE OR PROGNOSTIC BIOMARKER 
Prostate cancer is a heterogeneous disease with high variability in regards to 
therapeutical response and clinical outcome. Due to this variability the process 
of screening, diagnosing, therapy offers and monitoring can be difficult to the 
urologist, and achieving a successful outcome still remains a challenge. So a 
high demand in optimizing each step is crucial, leading to an increased interest 
in designing novel biomarkers. 
 
Previously, the importance of discovering new screening/diagnostic biomarkers 
was discussed, but the importance and the valuable contribution in clinical 
practice of predictive and prognostic biomarkers should not be discarded. The 
finding of new predictive markers would help divide different populations with 
respect to the outcome, for example response to determined/target treatment. 
Differently, a prognostic marker would help to know which population of patients 
has a risk for a certain outcome, in case standard treatment or no treatment is 
given. The two terms were carefully described in order to clarify and alert that 
predictive and prognostic are to different concepts, being frequently misused 
and wrongly interchangeably used. 
 
Since in the clinicopathological correlation analysis it was found a significant 
relationship between T-, M- and N-stage as also Gleason score with 
higher/lower levels of TKTL1, it would be interesting to perform a study with a 
higher number of patients in order to better clarify the clinical significance of 
TKTL1 expression in prostate cancer. Additionally, it would be interesting to 
conduct studies to analyze TKTL1 expression and patient’s outcome. A study of 
this magnitude is difficult to manage and design, but if in a near future TKTL1 
protein proves to be a potential biomarker or a potential target therapy, this kind 
of studies are crucial to perform  
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5.10.3 TKTL1 INHIBITION AS A CANCER TREATMENT 
Another point of relevance for further studies is the impact of TKTL1 inhibition in 
prostate cancer, reinforcing the idea of a potential therapeutic innovation. Since 
it has already been published that inhibition of TKTL1 activity resulted in a 
diminished tumour growth rate, further research efforts should focus on 
uncovering the mechanism behind this change. Such findings could open the 
door for new target therapies in different cancer, hopefully in prostate cancer 
too.  This concept has been proposed by Dr. Coy, which in 2005 invented a 
patent, which related to methods concerning the uses of antagonists or agonist 
of TKTL1 for treatment, detection and diagnosis of disorders associated with an 
altered transketolase (European patent EP 1701165 A1).  
 
A recent published study from 2016, showed the potentiality of oxythiamine as 
an inhibitor of TKTL1 [187]. Further studies should be encouraged in this area.  
 
An interesting study would be to evaluate the impact of TKTL1 inhibition in 
tumour growth or progression in prostate cancer. 
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6 CONCLUSION 
 
In our study, TKTL1 showed a high specificity (86.36%) and sensitivity (92.30%) 
to distinguish benign from malignant prostatic tissue in IHC. The TKTL1 protein 
immunoexpression pattern ranges from a low level in benign prostatic tissue, to 
moderate immunoexpression in organ-confined prostate cancer, and high in 
metastatic prostate cancer. An upregulation of TKTL1 expression in prostate 
cancer was evident, and multiple clinicopathological parameters correlated with 
TKTL1: M-stage, N-stage, T-stage and Gleason score. A significant difference 
in the median of TKTL1 expression was found between peritumoral tissue and 
benign tissue. Both are considered normal tissue when using the Gleason score 
grading, but TKTL1 score was found higher in peritumoral tissue comparing to 
benign. A finding, which raises new questions in the area of pre-malignant 
lesions and incentives further research in this area.  
Although the study revealed an association between TKTL1 expression with 
prostate cancer progression, the clinical value of TKTL1 is still unclear. Its place 
in the metabolic chain also makes it a potential therapeutic target, with the 
possibility of disrupting cancer cell metabolism. The applicability of TKTL1 in the 
clinical practice as an adjunct test in prostate cancer also warrants further 
investigation. 
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7 ABSTRACT 
 
Deregulated cellular energetics has been recently proposed as an emerging 
hallmark of cancer. Cancer cells, in aerobic conditions, show an increased 
glucose uptake and lactate secretion in order to support their rapid proliferation. 
Transketolase like 1 (TKTL1) helps cancer cells meet their energy demands 
and combat oxidative stress and has been reported to be over-expressed in 
several human tumours including urothelial carcinomas, ovarial, colon and 
breast carcinoma. However, there is few data on TKTL1 in prostatic 
adenocarcinoma (PCa). Prostate cancer is the second most common cancer 
among men worldwide, and an urgent need exists for new diagnostic, 
prognostic and predictive tests.   
In order to investigate TKTL1 expression in PCa in different stages of 
progression we included 124 tissue samples. Tumour tissue of 53 patients who 
underwent prostatectomy, as well as corresponding adjacent non-neoplastic 
prostate tissue were analyzed. A total of 45 patients with metastatic prostate 
cancer were also included. 26 patients were included as controls. From the 
TMA slides, we evaluated the expression of the TKTL1 protein, using the H-
score (score range from 0 until 300) by immunohistochemical analysis. Due to 
artefacts or insufficient data, tissues from 24 patients were excluded from the 
study, leaving a total of number of 100 eligible patients. 
TKTL1 expression was significantly higher in tumour tissue in comparison with 
normal tissue (243.13 (187.04, 295) compared to 100 (57.5, 105), p<0.001). 
The TKTL1 protein expression pattern ranges from a low level in benign 
prostatic tissue (100 (57.5, 105) to moderate expression in non-metastatic PCa 
(200 (172.19-254.38) and metastatic PCa (300 (222.50-300). In the group of 
patients with metastatic prostate cancer no difference was found between 
TKTL1 expressions in tissues from hormone-sensitive or hormone-refractory 
prostate cancer (p=0.9015). An upregulation of TKTL1 in prostate cancer was 
evident, multiple clinicopathological parameters showed significant relationship 
with high or low levels of TKTL1: M-stage (p=0.0023), T-stage (p=0.0027), N-
stage (p=0.0257) and Gleason score (p=0.0075). 
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A significant difference was found between peritumoral (non-malignant) prostate 
tissue and benign tissue, a higher TKTL1 expression being present in 
peritumoral tissue (135.42 (100-195.16) compared with 100 (57.5-105), 
p=0.006). TKTL1 expression reflects an intrinsic process of glucose metabolism 
reprogramming and therefore is not detectable through the diagnostic Gleason 
score grading system, since this classification is only based on morphological 
alterations. Both group tissues were classified as non-malignant, in spite of a 
signs of tumorigenesis process being seen in the non-malignant peritumoral 
tissue. 
TKTL1 protein is still not explored enough and has not yet reached its final 
potential. This enzyme could be a potential candidate as an adjunct test for 
prostate cancer or as a targeted inhibitor of tumour growth.   
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8 ZUSAMMENFASSUNG 
 
Deregulierte zelluläre Energetiken wurden vor kurzem als ein sich neu 
herausbildendes Kennzeichen von Krebserkrankungen vorgeschlagen. 
Krebszellen zeigen, unter aeroben Bedingungen, eine erhöhte 
Glukoseaufnahme und Laktatsekretion um ihre rasche proliferation zu 
ermöglichen. Transketolase like 1 (TKTL1) hilft Krebszellen dabei ihren 
Energiebedarf zu  decken und gegen oxidativen Stress anzukämpfen. 
Berichten zufolge ist TKTL1 in mehreren menschlichen Tumoren 
überexprimiert, darunter das Urothelkarzinom, Ovarialkarzinom, Kolonkarzinom 
und Mamakarzinom. Jedoch stehen nur wenige Daten über TKTL1 in 
Prostatakarzinomen zur Verfügung. Prostatakrebs ist die zweithäufigste 
Krebserkrankung in Männern weltweit.  Es besteht ein dringender Bedarf nach 
neuen diagnostischen und  prognostischen Methoden sowie predikativen Tests.  
Um die TKTL1 Expression in PCa in unterschiedlichen Progressionsstadien zu 
untersuchen, bezogen wir in diese Studie 124 Gewebeproben ein. 
Tumorgewebe und non-malign peritumorales Gewebe aus Prostatektomien von 
53 Patienten wurde analysiert. Auch wurden 45 Patienten mit metastasierenden 
Prostatakarzinomen in dieser Studie untersucht. 26 Patienten wurden als 
Kontrollen miteinbezogen. Aus den TMA Schnitten evaluierten wir die 
Expression des TKTL1 Proteins  mit Hilfe des H-scores (von 0 bis 300) mit 
immunohistochemischer Analyse. Aufgrund von Artefakten oder 
unzureichenden Daten wurde Gewebe von 24 Patienten aus der Studie 
ausgeschlossen, was zu einer Gesamtzahl von 100 evaluierbaren Patienten 
führt. 
TKTL1 Expression war in Tumorgewebe signifikant erhöht im Vergleich zu 
normalem Gewebe (243.13 (187.04- 295) vs 100 (57.5- 105), p<0.001). 
Das Immunoexpressionsmuster des TKTL1 Proteins reicht von einem niedrigen 
Niveau in benignem Prostatagewebe (100 (57.5-105) über moderate 
Immunoexpression in nicht-metastasierenden PCa (200 (172.19-254.38) und 
metastasierendem Prostatakrebs (300 (222.50-300). 
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In der Patientengruppe mit metastasierendem Prostatakrebs wurde kein 
Unterschied in TKTL1 Expression in Geweben aus hormon-sensiblem oder 
hormon-refraktärem Prostatakrebs gefunden (p=0.9015). Die hochregulation 
von TKTL in Prostatakrebs war eindeutig, und wurden multiplen klinisch-
pathologische Korrelationen mit dem M-Stadium (p=0.0023), T-stadium 
(p=0.0027), N-stadium (p=0.0257) und Gleason score (p=0.0075) gefunden. Ein 
signifikanter Unterschied zwischen peritumoralem (non-malignem) und 
benignem Prostatagewebe zeigte eine erhöhte TKTL1 Expression in 
peritumoralem Gewebe (135.42 (100-195.16) vs. 100 (57.5-105), p=0.006). 
TKTL1 expression reflektiert einen intrinsischen Prozess der 
Neuprogrammierung des Glukosemetabolismuses, und ist nicht mit dem 
diagnostischen Gleason score Bewertungssystem bewertbar, da diese 
Klassifikation nur auf morphologischen Veränderungen basiert. Beide 
Gewebegruppen wurden als non-malign klassifiziert, trotz Anzeichen  von 
Tumorgenesisprozessen die in dem non-malignem peritumoralem Gewebe 
festgestellt wurden. 
Das TKTL1 Protein ist noch nicht genug erforscht worden und hat sein  
Potential bisher noch nicht erreicht. Dieses Enzym könnte künftig ein 
potentieller Kandidat (als eine Zusatzuntersuchung) für Prostatakrebs oder ein 
zielgerichteter Inhibitor des Tumorwachstums werden. 
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